Salts of pyrrolotriazine derivatives useful as TAM inhibitors

CN118930549APending Publication Date: 2024-11-12INCYTE CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410706110.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-08-03
Filing Date
2018-09-26
Publication Date
2024-11-12

AI Technical Summary

Benefits of technology

[0367] Tablets or pills of the present invention may be coated or otherwise compounded to provide dosage forms that provide the advantage of prolonged action. For example, a tablet or pill may contain an inner dosage and an outer dosage component in the form of an envelope surrounding the former. The two components may be separated by an enteric coating layer that serves to resist disintegration in the stomach and allow the inner component to pass intact into the duodenum or to delay release. A variety of materials may be used for such casings or coatings, including many polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol, and cellulose acetate.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930549A_ABST
    Figure CN118930549A_ABST
Patent Text Reader

Abstract

The present application provides N-(4-(4-amino-7-(1-isobutyryl piperidine-4-yl) pyrrolo [1, 2-f] [1, 2, 4] triazine-5-yl) phenyl)-1-isopropyl-2, 4-dioxo-3-(pyridin-2-yl)-1, 2, 3, 4-tetrahydropyrimidine-5-carboxamide (I) and N-(4-(4-amino-7-(1-isobutyryl piperidine-4-yl) pyrrolo [1, 2-f] [1, 2, 4] triazine-5-yl) phenyl)-1-isopropyl-2, 2, 3, 4-tetrahydropyrimidine-5-carboxamide (I), and a pharmaceutically acceptable salt thereof. The present invention relates to a salt form of 1, 2, 4-dioxo-3-phenyl-1, 2, 3, 4-tetrahydropyrimidine-5-carboxamide (II), which is useful as an inhibitor of TAM kinase, and a salt form of 1, 2, 4-dioxo-3-phenyl-1, 2, 3, 4-tetrahydropyrimidine-5-carboxamide (II); and related methods and intermediates thereof. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an invention patent application with an application date of September 26, 2018, application number 201880073539.6 (international application number PCT / US2018 / 052925), and name “Salts of pyrrolotriazine derivatives useful as TAM inhibitors”. Technical Field

[0002] The present disclosure provides salt forms of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide, which can be used as inhibitors of TAM kinases; and related methods and intermediates thereof. Background Art

[0003] Receptor tyrosine kinases (RTKs) are cell surface proteins that transmit signals from the extracellular environment to the cytoplasm and nucleus to regulate cellular events such as survival, growth, proliferation, differentiation, adhesion and migration.

[0004] The TAM subfamily consists of three RTKs, including Tyro3, ​​AXL and Mer (Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). TAM kinases are characterized by an extracellular ligand binding domain consisting of two immunoglobulin-like domains and two type III fibronectin domains. Two ligands of TAM kinases have been identified, i.e., growth arrest-specific protein 6 (GAS6) and protein S (PROS1). GAS6 can bind to all three TAM kinases and activate them, while PROS1 is a ligand for Mer and Tyro3 (Graham et al., 2014, Nature Reviews Cancer 14, 769-785).

[0005] AXL (also known as UFO, ARK, JTK11 and TYRO7) was originally identified as a transforming gene from DNA of patients with chronic myeloid leukemia (O'Bryan et al., 1991, Mol Cell Biol 11, 5016-5031; Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). GAS6 binds to AXL and induces subsequent autophosphorylation and activation of AXL tyrosine kinase. AXL activates several downstream signaling pathways, including PI3K-Akt, Raf-MAPK, PLC-PKC (Feneyrolles et al., 2014, Molecular Cancer Therapeutics 13, 2141-2148; Linger et al., 2008, Advances in Cancer Research 100, 35-83).

[0006] MER (also known as MERTK, EYK, RYK, RP38, NYK and TYRO12) was originally identified as a phosphorylated protein from a lymphoblastoid expression pool (Graham et al., 1995, Oncogene 10, 2349-2359; Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). Both GAS6 and PROS1 can bind to Mer and induce phosphorylation and activation of Mer kinase (Lew et al., 2014). Like AXL, MER activation also transmits downstream signaling pathways, including PI3K-Akt and Raf-MAPK (Linger et al., 2008, Advances in Cancer Research 100, 35-83).

[0007] TYRO3 (also known as DTK, SKY, RSE, BRT, TIF, ETK2) was originally identified by PCR-based cloning studies (Lai et al., Neuron 6, 691-70, 1991; Graham et al., 2014, Nature Reviews Cancer 14, 769-785; Linger et al., 2008, Advances in Cancer Research 100, 35-83). Both ligands, GAS6 and PROS1, can bind to TYRO3 and activate it. Although the signaling pathways downstream of TYRO3 activation are rarely studied in TAM RTKs, both the PI3K-Akt and Raf-MAPK pathways appear to be involved (Linger et al., 2008, Advances in Cancer Research 100, 35-83). AXL, MER, and TYRO3 were found to be overexpressed in cancer cells.

[0008] Therefore, there is a need for compounds and methods of use thereof for modulating TAM kinases to treat cancer. Summary of the invention

[0009] The present application provides a salt of a compound of formula I:

[0010]

[0011] The compounds of formula I are useful as TAM inhibitors.

[0012] The present application also provides a maleate salt of the compound of formula I.

[0013] The present application also provides a method for preparing a salt of a compound of formula I. The present application provides a salt of a compound of formula II:

[0014]

[0015] The compounds of formula II are useful as TAM inhibitors.

[0016] The present application also provides a hemisulfate salt of the compound of formula II.

[0017] The present application also provides a phosphate salt of the compound of formula II.

[0018] The present application also provides a maleate salt of the compound of formula II.

[0019] The present application also provides the hydrochloride salt of the compound of formula II.

[0020] The present application also provides salicylate salts of the compound of formula II.

[0021] The present application also provides a methanesulfonate salt (ie, mesylate salt) of the compound of Formula II.

[0022] The present application also provides an ethanesulfonate salt (ie, ethanesulfonate) of the compound of formula II.

[0023] The present application also provides a method for preparing a salt of the compound of formula II.

[0024] The present application also provides a pharmaceutical composition comprising any one of the salts of the compound of formula I and the salts of the compound of formula II.

[0025] The present application also provides a method for inhibiting TAM kinase, wherein the method comprises contacting the TAM kinase with any one of the salts of the compound of formula I and the salts of the compound of formula II.

[0026] The present application also provides a method for inhibiting AXL and MER kinases, wherein the method comprises contacting the AXL or MER kinase with any one of the salts of the compound of formula I and the salts of the compound of formula II.

[0027] The present application also provides a method for treating cancer in a patient, comprising administering to the patient a therapeutically effective amount of any one of the salts of the compound of Formula I and the salts of the compound of Formula II. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 An XRPD pattern representative of Compound 1 maleate salt Form I is shown.

[0029] Figure 2 A DSC thermogram representing Compound 1 maleic acid Form I is shown.

[0030] Figure 3 Shown are TGA data representative of Compound 1 maleate salt Form I.

[0031] Figure 4 An XRPD pattern representative of the phosphate salt of Compound II is shown.

[0032] Figure 5 A DSC thermogram representing the phosphate salt of Compound II is shown.

[0033] Figure 6 TGA data representative of the phosphate salt of Compound II are shown.

[0034] Figure 7 An XRPD pattern representative of Compound II maleate salt is shown.

[0035] Figure 8 A DSC thermogram representative of the maleate salt of Compound II is shown.

[0036] Fig. 9TGA data representative of Compound II maleate salt are shown.

[0037] Fig.10 An XRPD pattern representative of Compound II hemisulfate salt is shown.

[0038] Fig.11 A DSC thermogram representing the hemisulfate salt of Compound II is shown.

[0039] Fig.12 TGA data representative of Compound II hemisulfate salt are shown.

[0040] Fig.13 An XRPD pattern representative of Compound II's hydrochloride salt is shown.

[0041] Fig.14 A DSC thermogram representing the hydrochloride salt of Compound II is shown.

[0042] Fig.15 TGA data representative of Compound II's hydrochloride salt are shown.

[0043] Fig.16 An XRPD pattern representative of Compound II salicylate salt is shown.

[0044] Fig.17 A DSC thermogram representative of Compound II salicylate salt is shown.

[0045] Fig.18 TGA data representative of Compound II salicylate salt are shown.

[0046] Fig.19 An XRPD pattern representative of the mesylate salt of Compound II is shown.

[0047] Fig. 20 A DSC thermogram representing the mesylate salt of Compound II is shown.

[0048] Fig.21 TGA data representative of Compound II mesylate salt are shown.

[0049] Fig. 22 An XRPD pattern representative of Compound II ethanesulfonate salt is shown.

[0050] Fig.23 A DSC thermogram representing the ethanesulfonate salt of Compound II is shown.

[0051] Fig.24 TGA data representative of Compound II ethanesulfonate salt are shown.

[0052] Fig.25 An XRPD pattern representative of Compound 1 maleate salt Form II is shown.

[0053] Fig.26 An XRPD pattern representative of Compound 1 maleate salt Form III is shown.

[0054] Fig. 27 Shown is a DSC thermogram representing Compound 1 Maleic Acid Form III.

[0055] Fig.28 Shown are TGA data representative of Compound 1 maleate salt Form III.

[0056] Fig.29 An XRPD pattern representative of Compound 1 maleate salt Form IV is shown.

[0057] Fig.30 Shown is a DSC thermogram representing Compound 1 Maleic Acid Form IV.

[0058] Fig.31 Shown are TGA data representative of Compound 1 maleate salt Form IV.

[0059] Fig.32 An XRPD pattern representative of Compound 1 maleate salt Form V is shown.

[0060] Fig.33 A DSC thermogram representing Compound 1 Maleic Acid Form V is shown.

[0061] Fig.34 TGA data representative of Compound 1 maleate salt Form V is shown. DETAILED DESCRIPTION

[0062] Compounds and salts

[0063] The present application provides a salt of a compound of formula I:

[0064]

[0065]

[0066] or pharmaceutically acceptable hydrates and solvates thereof, which can be used as TAM inhibitors.

[0067] Therefore, in some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (also referred to herein as the maleate salt of the compound of formula I, the maleate salt of compound I, the maleate salt of compound I, or any variation thereof).

[0068] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide to maleic acid.

[0069] Different forms of the same substance have different overall properties with regard to, for example, hygroscopicity, solubility, stability, etc. The form with a high melting point usually has good thermodynamic stability, thereby helping to extend the shelf life of the pharmaceutical preparation containing the solid form. The form with a lower melting point is usually less stable thermodynamically, but has the advantage that it has an increased water solubility, thereby converting into an increased drug bioavailability. The form with weak hygroscopicity is desirable because of its thermal stability and moisture stability, and resists degradation during long-term storage.

[0070] Solid forms (e.g., crystalline forms) described herein may have certain advantages, for example, they may have desirable properties, such as ease of handling, ease of processing, storage stability, and ease of purification. In addition, crystalline forms may be used to improve performance characteristics of drug products, such as dissolution profiles, shelf life, and bioavailability.

[0071] In some embodiments, the maleate salt of the compound of formula I provided herein is crystalline. As used herein, "crystallization" or "crystalline form" is intended to refer to a certain lattice configuration of a crystalline material. Different crystalline forms of the same material typically have different lattices (e.g., unit cells), which can be attributed to different physical properties unique to each crystalline form. In some cases, different lattice configurations have different water or solvent contents.

[0072] Different salt forms can be identified by solid state characterization methods, such as by X-ray powder diffraction (XRPD). Other characterization methods, such as differential scanning calorimetry (DSC), thermogravimetric analysis (TGA), dynamic vapor sorption (DVS), etc., are more helpful in identifying the forms and in determining stability and solvent / water content.

[0073] The XRPD pattern of reflection (peak) is typically regarded as the fingerprint of a specific crystalline form. It is well known that the relative intensity of the XRPD peak can vary widely depending on the sample preparation technique, crystal size distribution, various filters used, sample fixation degree and the specific instrument used. In some cases, new peaks may be observed, or existing peaks may disappear, depending on the instrument type or setting. As used herein, the term "peak" refers to a reflection with a relative height / intensity accounting for at least about 4% of the maximum peak height / intensity. In addition, instrument deviations and other factors may affect 2θ values. Therefore, peak designations, such as those reported herein, can vary plus or minus about 0.2 ° (2θ), and the terms "substantially" and "about" as used herein in the context of XRPD are intended to cover the above-mentioned deviations.

[0074] Likewise, temperature readings associated with DSC, TGA or other thermal experiments can vary by about ±3°C, depending on the instrument, specific settings, sample preparation, etc. Therefore, references herein to a crystalline form having a DSC thermogram "substantially" as shown in any of the accompanying drawings or the term "about" should be understood to include such deviations.

[0075] In some embodiments, the salts and compounds described herein (e.g., compounds of Formula I or maleates of compounds of Formula I) are substantially isolated. "Substantially isolated" means that the salt or compound is at least partially or substantially separated from the environment in which it is formed or detected. Partial separation can include, for example, a composition rich in salts described herein. Substantially separated can include a composition containing at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95%, at least about 97%, or at least about 99% of the salts described herein or their salts by weight. Methods for separating compounds and their salts are conventional in the art.

[0076] The maleate salt of the compound of Formula I can be prepared in various crystalline forms, including, for example, Form I, Form II, Form III, Form IV or Form V.

[0077] Maleate salt form I of the compound of formula I:

[0078] Provided herein are embodiments (i) to (x) of the crystalline form of the compound of Formula I described in Example 1 and Example 7 below, referred to as Form I.

[0079] (i) In some embodiments, the maleate salt of the compound of Formula I has at least one XRPD peak in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0080] (ii) In some embodiments, the maleate salt of the compound of Formula I has at least two XRPD peaks in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0081] (iii) In some embodiments, the maleate salt of the compound of Formula I has at least three XRPD peaks in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0082] (iv) In some embodiments, the maleate salt of the compound of Formula I has at least four XRPD peaks in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0083] (v) In some embodiments, the maleate salt of the compound of Formula I comprises the following XRPD peaks in terms of 2θ: about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0084] (vi) In some embodiments, the maleate salt of the compound of Formula I comprises the following XRPD peaks in terms of 2θ: about 4.3°, about 8.4°, and about 13.2°.

[0085] (vii) In some embodiments, the maleate salt of the compound of Formula I has substantially Figure 1 XRPD distribution shown.

[0086] (viii) In some embodiments, the maleate salt of the compound of Formula I has a DSC thermogram with an endothermic peak at about 211°C.

[0087] (ix) In some embodiments, the maleate salt of the compound of Formula I has substantially Figure 2 DSC thermogram shown.

[0088] (x) In some embodiments, the maleate salt of the compound of Formula I has substantially Figure 3 TGA thermogram shown.

[0089] Maleate salt form II of the compound of formula I:

[0090] Provided herein is a crystalline form of the compound of Formula I described in Example 16 and Example 17 below, referred to as Form II.

[0091] In some embodiments, the maleate salt Form II of the compound of Formula I has at least one XRPD peak with respect to 2θ selected from about 3.8°, about 7.8°, about 23.5°, and about 26.0°.

[0092] In some embodiments, the maleate salt Form II of the compound of Formula I has at least two XRPD peaks with respect to 2θ selected from about 3.8°, about 7.8°, about 23.5°, and about 26.0°.

[0093] In some embodiments, the maleate salt Form II of the compound of Formula I has at least three XRPD peaks with respect to 2θ selected from about 3.8°, about 7.8°, about 23.5°, and about 26.0°.

[0094] In some embodiments, the maleate salt Form II of the compound of Formula I has XRPD peaks in terms of 2θ including: about 3.8°, about 7.8°, about 23.5°, and about 26.0°.

[0095] In some embodiments, the maleate salt Form II of the compound of Formula I has XRPD peaks in terms of 2θ including: about 3.8°, about 7.8°, and about 23.5°.

[0096] In some embodiments, the maleate salt form II of the compound of Formula I has substantially Fig.25 XRPD distribution shown in .

[0097] Maleate salt form III of the compound of formula I:

[0098] Provided herein is a crystalline form of the compound of Formula I described in Examples 16 and 18 below, referred to as Form III.

[0099] In some embodiments, the maleate salt form III of the compound of Formula I has at least one XRPD peak with respect to 2θ selected from about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6°.

[0100] In some embodiments, the maleate salt Form III of the compound of Formula I has at least two XRPD peaks with respect to 2θ selected from about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6°.

[0101] In some embodiments, the maleate salt Form III of the compound of Formula I has at least three XRPD peaks with respect to 2θ selected from about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6°.

[0102] In some embodiments, the maleate salt Form III of the compound of Formula I has at least four XRPD peaks with respect to 2θ selected from about 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6°.

[0103] In some embodiments, the maleate salt Form III of the compound of Formula I comprises the following XRPD peaks with respect to 2θ: 3.8°, about 7.7°, about 12.1°, about 18.9°, and about 20.6°.

[0104] In some embodiments, the maleate salt Form III of the compound of Formula I comprises the following XRPD peaks in terms of 2θ: about 3.8°, about 7.7°, about 12.1°, and about 18.9°.

[0105] In some embodiments, the maleate salt form III of the compound of Formula I has substantially Fig.26 The XRPD distribution shown in .

[0106] In some embodiments, the maleate salt form III of the compound of formula I has a DSC thermogram with endothermic peaks at about 165.4°C and about 195.4°C. In some embodiments, the maleate salt form III of the compound of formula I has a DSC thermogram with endothermic peaks at about 165.4°C. In some embodiments, the maleate salt form III of the compound of formula I has a DSC thermogram with endothermic peaks at about 195.4°C.

[0107] In some embodiments, the maleate salt form III of the compound of Formula I has substantially Fig. 27 DSC thermogram shown.

[0108] In some embodiments, the maleate salt form III of the compound of Formula I has substantially Fig.28 TGA thermogram shown.

[0109] Maleate salt form IV of the compound of formula I:

[0110] Provided herein is a crystalline form of the compound of Formula I described in Example 16 and Example 19 below, designated Form IV.

[0111] In some embodiments, the maleate salt Form IV of the compound of Formula I has at least one XRPD peak with respect to 2θ selected from about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°.

[0112] In some embodiments, the maleate salt Form IV of the compound of Formula I has at least two XRPD peaks with respect to 2θ selected from about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°.

[0113] In some embodiments, the maleate salt Form IV of the compound of Formula I has at least three XRPD peaks with respect to 2θ selected from about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°.

[0114] In some embodiments, the maleate salt Form IV of the compound of Formula I has at least four XRPD peaks with respect to 2θ selected from about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°.

[0115] In some embodiments, the maleate salt Form IV of the compound of Formula I comprises the following XRPD peaks with respect to 2θ: about 3.9°, about 4.6°, about 7.8°, about 9.1°, and about 22.8°.

[0116] In some embodiments, the maleate salt Form IV of the compound of Formula I comprises the following XRPD peaks in terms of 2θ: about 3.9°, about 4.6°, about 7.8°, and about 9.1°.

[0117] In some embodiments, the maleate salt form IV of the compound of Formula I has substantially Fig.29 XRPD distribution shown in .

[0118] In some embodiments, the maleate salt form IV of the compound of Formula I has a DSC thermogram with endothermic peaks at about 152.1°C and 202.6°C. In some embodiments, the maleate salt form IV of the compound of Formula I has a DSC thermogram with endothermic peaks at about 152.1°C. In some embodiments, the maleate salt form IV of the compound of Formula I has a DSC thermogram with endothermic peaks at about 202.6°C.

[0119] In some embodiments, the maleate salt form IV of the compound of Formula I has substantially Fig.30 DSC thermogram shown.

[0120] In some embodiments, the maleate salt form IV of the compound of Formula I has substantially Fig.31 TGA thermogram shown.

[0121] Maleate salt form V of the compound of formula I:

[0122] Provided herein is a crystalline form of the compound of Formula I, designated Form V, described in Examples 16 and 20 below.

[0123] In some embodiments, the maleate salt Form V of the compound of Formula I has at least one XRPD peak with respect to 2θ selected from about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3°.

[0124] In some embodiments, the maleate salt Form V of the compound of Formula I has at least two XRPD peaks with respect to 2θ selected from about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3°.

[0125] In some embodiments, the maleate salt Form V of the compound of Formula I has at least three XRPD peaks with respect to 2θ selected from about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3°.

[0126] In some embodiments, the maleate salt Form V of the compound of Formula I has at least four XRPD peaks with respect to 2θ selected from about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3°.

[0127] In some embodiments, the maleate salt Form V of the compound of Formula I comprises the following XRPD peaks with respect to 2θ: about 4.1°, about 8.3°, about 8.8°, about 18.0°, and about 27.3°.

[0128] In some embodiments, the maleate salt Form V of the compound of Formula I comprises the following XRPD peaks with respect to 2θ: about 4.1°, about 8.3°, about 8.8°, and about 27.3°.

[0129] In some embodiments, the maleate salt form V of the compound of Formula I has substantially Fig.32 XRPD distribution shown in .

[0130] In some embodiments, the maleate salt Form V of the compound of Formula I has a DSC thermogram with an endothermic peak at about 200.1 °C.

[0131] In some embodiments, the maleate salt form V of the compound of Formula I has substantially Fig.33 DSC thermogram shown.

[0132] In some embodiments, the maleate salt form V of the compound of Formula I has substantially Fig.34 TGA thermogram shown.

[0133] The present application also provides a salt of a compound of formula II:

[0134]

[0135] or pharmaceutically acceptable hydrates and solvates thereof, which can be used as TAM inhibitors.

[0136] Therefore, in some embodiments, the present application provides a salt selected from the following:

[0137] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide phosphate;

[0138] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate;

[0139] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate;

[0140] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hydrochloride;

[0141] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide salicylate;

[0142] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide methanesulfonate; and

[0143] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide ethanesulfonate,

[0144] or pharmaceutically acceptable solvates and hydrates thereof.

[0145] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide phosphate (also referred to herein as the phosphate salt of the compound of formula II, the phosphate salt of compound II, the phosphate salt of compound II, or any variation thereof).

[0146] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to phosphoric acid.

[0147] In some embodiments, the phosphate salt of the compound of Formula II is crystalline.

[0148] In some embodiments, the phosphate salt of the compound of Formula II is substantially isolated.

[0149] In some embodiments, the phosphate salt of the compound of formula II has at least one XRPD peak selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in terms of 2θ. In some embodiments, the phosphate salt of the compound of formula II has at least two XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in terms of 2θ. In some embodiments, the phosphate salt of the compound of formula II has at least three XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in terms of 2θ. In some embodiments, the phosphate salt of the compound of formula II has at least four XRPD peaks selected from about 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3° in terms of 2θ. In some embodiments, the phosphate salt of the compound of Formula II comprises the following XRPD peaks in terms of 2θ: 5.3°, about 9.1°, about 14.9°, about 15.8°, and about 19.3°.

[0150] In some embodiments, the phosphate salt of the compound of Formula II has substantially Figure 4 XRPD distribution shown in .

[0151] In some embodiments, the phosphate salt of the compound of Formula II has a DSC thermogram with an endothermic peak at about 257.2° C. In some embodiments, the phosphate salt of the compound of Formula II has substantially Figure 5 In some embodiments, the phosphate salt of the compound of formula II has substantially Figure 6 TGA thermogram shown.

[0152] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (also referred to herein as the maleate salt of the compound of formula II, the maleate salt of compound II, the maleate salt of compound II, or any variation thereof).

[0153] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to maleic acid.

[0154] In some embodiments, the maleate salt of the compound of Formula II is crystalline.

[0155] In some embodiments, the maleate salt of the compound of Formula II is substantially isolated.

[0156] In some embodiments, the maleate salt of the compound of formula II has at least one XRPD peak selected from about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2° in terms of 2θ. In some embodiments, the maleate salt of the compound of formula II has at least two XRPD peaks selected from about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2° in terms of 2θ. In some embodiments, the maleate salt of the compound of formula II has at least three XRPD peaks selected from about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2° in terms of 2θ. In some embodiments, the maleate salt of the compound of formula II has at least four XRPD peaks selected from about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2° in terms of 2θ. In some embodiments, the maleate salt of the compound of Formula II comprises the following XRPD peaks in terms of 2θ: about 4.5°, about 6.5°, about 14.1°, about 24.0°, and about 28.2°.

[0157] In some embodiments, the maleate salt of the compound of Formula II has substantially Figure 7 XRPD distribution shown.

[0158] In some embodiments, the maleate salt of the compound of formula II has a DSC thermogram with endothermic peaks at about 194.8°C and / or about 239.7°C. In some embodiments, the maleate salt of the compound of formula II has substantially Figure 8In some embodiments, the maleate salt of the compound of formula II has substantially Fig. 9 TGA thermogram shown in .

[0159] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (also referred to herein as the hemisulfate salt of the compound of formula II, the hemisulfate salt of compound II, the hemisulfate salt of compound II, or any variation thereof).

[0160] In some embodiments, the salt is a 1:0.5 (ie, 2:1) stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to sulfuric acid.

[0161] In some embodiments, the hemisulfate salt of the compound of Formula II is crystalline.

[0162] In some embodiments, the hemisulfate salt of the compound of Formula II is substantially isolated.

[0163] In some embodiments, the hemisulfate salt of the compound of Formula II has at least one XRPD peak selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9° in terms of 2θ. In some embodiments, the hemisulfate salt of the compound of Formula II has at least two XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9° in terms of 2θ. In some embodiments, the hemisulfate salt of the compound of Formula II has at least three XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9° in terms of 2θ. In some embodiments, the hemisulfate salt of the compound of Formula II has at least four XRPD peaks selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9° in terms of 2θ. In some embodiments, the hemisulfate salt of the compound of Formula II comprises the following XRPD peaks in terms of 2θ: about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9°.

[0164] In some embodiments, the hemisulfate salt of the compound of Formula II has substantially Fig.10 The XRPD distribution shown in .

[0165] In some embodiments, the hemisulfate salt of the compound of Formula II has a DSC thermogram with an endothermic peak at about 289.4° C. In some embodiments, the hemisulfate salt of the compound of Formula II has substantially Fig.11 In some embodiments, the hemisulfate salt of the compound of formula II has substantially Fig.12 TGA thermogram shown in .

[0166] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hydrochloride (also referred to herein as the hydrochloride salt of the compound of formula II, the hydrochloride salt of compound II, the hydrochloride salt of compound II, or any variation thereof).

[0167] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to hydrochloric acid.

[0168] In some embodiments, the hydrochloride salt of the compound of Formula II is crystalline.

[0169] In some embodiments, the hydrochloride salt of the compound of Formula II is substantially isolated.

[0170] In some embodiments, the hydrochloride salt of the compound of formula II has at least one XRPD peak selected from about 6.5°, about 9.7°, about 14.9°, about 21.5°, and about 23.9° in terms of 2θ. In some embodiments, the hydrochloride salt of the compound of formula II has at least two XRPD peaks selected from about 6.5°, about 9.7°, about 14.9°, about 21.5°, and about 23.9° in terms of 2θ. In some embodiments, the hydrochloride salt of the compound of formula II has at least three XRPD peaks selected from about 6.5°, about 9.7°, about 14.9°, about 21.5°, and about 23.9° in terms of 2θ. In some embodiments, the hydrochloride salt of the compound of formula II has at least four XRPD peaks selected from about 6.5°, about 9.7°, about 14.9°, about 21.5°, and about 23.9° in terms of 2θ. In some embodiments, the hydrochloride salt of the compound of Formula II comprises the following XRPD peaks in terms of 2θ: about 6.5°, about 9.7°, about 14.9°, about 21.5°, and about 23.9°.

[0171] In some embodiments, the hydrochloride salt of the compound of Formula II has substantially Fig.13 The XRPD distribution shown in .

[0172] In some embodiments, the hydrochloride salt of the compound of formula II has a DSC thermogram with an endothermic peak at about 190° C. In some embodiments, the hydrochloride salt of the compound of formula II has substantially Fig.14 In some embodiments, the hydrochloride salt of the compound of formula II has substantially Fig.15 TGA thermogram shown in .

[0173] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide salicylate (also referred to herein as salicylate of compound of formula II, salicylate of compound II, salicylate of compound II, or any variation thereof).

[0174] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide and salicylic acid.

[0175] In some embodiments, the salicylate salt of the compound of Formula II is crystalline.

[0176] In some embodiments, the salicylate salt of the compound of Formula II is substantially isolated.

[0177] In some embodiments, the salicylate of the compound of formula II has at least one XRPD peak selected from about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9° in terms of 2θ. In some embodiments, the salicylate of the compound of formula II has at least two XRPD peaks selected from about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9° in terms of 2θ. In some embodiments, the salicylate of the compound of formula II has at least three XRPD peaks selected from about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9° in terms of 2θ. In some embodiments, the salicylate of the compound of formula II has at least four XRPD peaks selected from about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9° in terms of 2θ. In some embodiments, the salicylate salt of the compound of Formula II comprises the following XRPD peaks in terms of 2θ: about 7.3°, about 14.4°, about 15.7°, about 19.9°, and about 21.9°.

[0178] In some embodiments, the salicylate salt of the compound of Formula II has substantially Fig.16 The XRPD distribution shown in .

[0179] In some embodiments, the salicylate salt of the compound of Formula II has a DSC thermogram with endothermic peaks at about 181.7°C, about 224.9°C, and / or 264.5°C. In some embodiments, the salicylate salt of the compound of Formula II has substantially Fig.17 In some embodiments, the salicylate salt of the compound of Formula II has substantially Fig.18 TGA thermogram shown in .

[0180] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide methanesulfonate (also referred to herein as the methanesulfonate of the compound of formula II, the methanesulfonate of compound II, the methanesulfonate of compound II, or any variation thereof).

[0181] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to methanesulfonic acid.

[0182] In some embodiments, the mesylate salt of the compound of Formula II is crystalline.

[0183] In some embodiments, the mesylate salt of the compound of Formula II is substantially isolated.

[0184] In some embodiments, the mesylate salt of the compound of formula II has at least one XRPD peak selected from about 5.0°, about 8.2°, about 13.2°, and about 16.9° in terms of 2θ. In some embodiments, the mesylate salt of the compound of formula II has at least two XRPD peaks selected from about 5.0°, about 8.2°, about 13.2°, and about 16.9° in terms of 2θ. In some embodiments, the mesylate salt of the compound of formula II has at least three XRPD peaks selected from about 5.0°, about 8.2°, about 13.2°, and about 16.9° in terms of 2θ. In some embodiments, the mesylate salt of the compound of formula II includes the following XRPD peaks in terms of 2θ: about 5.0°, about 8.2°, about 13.2°, and about 16.9°.

[0185] In some embodiments, the mesylate salt of the compound of Formula II has substantially Fig.19 XRPD distribution shown in .

[0186] In some embodiments, the mesylate salt of the compound of Formula II has a DSC thermogram with an endothermic peak at about 174.8° C. In some embodiments, the mesylate salt of the compound of Formula II has substantially Fig. 20 In some embodiments, the mesylate salt of the compound of formula II has substantially Fig.21 TGA thermogram shown in .

[0187] In some embodiments, the present application provides N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide ethanesulfonate (also referred to herein as the ethanesulfonate of the compound of formula II, the ethanesulfonate of compound II, the ethanesulfonate of compound II, or any variation thereof).

[0188] In some embodiments, the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide to ethanesulfonic acid.

[0189] In some embodiments, the ethanesulfonate salt of the compound of Formula II is crystalline.

[0190] In some embodiments, the ethanesulfonate salt of the compound of Formula II is substantially isolated.

[0191] In some embodiments, the ethanesulfonate salt of the compound of formula II has at least one XRPD peak selected from about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5° in terms of 2θ. In some embodiments, the ethanesulfonate salt of the compound of formula II has at least two XRPD peaks selected from about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5° in terms of 2θ. In some embodiments, the ethanesulfonate salt of the compound of formula II has at least three XRPD peaks selected from about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5° in terms of 2θ. In some embodiments, the ethanesulfonate salt of the compound of formula II has at least four XRPD peaks selected from about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5° in terms of 2θ. In some embodiments, the ethanesulfonate salt of the compound of Formula II comprises the following XRPD peaks in terms of 2θ: about 4.9°, about 7.6°, about 15.4°, about 16.8°, and about 17.5°. In some embodiments, the ethanesulfonate salt of the compound of Formula II comprises the following XRPD peaks in terms of 2θ: about 4.9°, about 7.6°, about 15.4°, and about 17.5°.

[0192] In some embodiments, the ethanesulfonate salt of the compound of Formula II has substantially Fig. 22 XRPD distribution shown in .

[0193] In some embodiments, the ethanesulfonate salt of the compound of Formula II has a DSC thermogram with an endothermic peak at about 187.7° C. In some embodiments, the ethanesulfonate salt of the compound of Formula II has substantially Fig.23 In some embodiments, the ethanesulfonate salt of the compound of formula II has substantially Fig.24 TGA thermogram shown in .

[0194] method

[0195] The present application also provides a method for preparing a salt of formula I:

[0196]

[0197] Thus, provided herein is a method for preparing the salt N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, the method comprising reacting a compound of formula I with maleic acid to form the salt. The method for preparing the maleate salt of the compound of formula I is shown in Scheme 1 and described in Example 1.

[0198] In some embodiments, about 1 equivalent of maleic acid is used based on 1 equivalent of the compound of Formula I.

[0199] In some embodiments, reacting the compound of Formula I with maleic acid is carried out in the presence of a solvent component.

[0200] In some embodiments, the solvent component comprises methanol.

[0201] In some embodiments, the solvent component comprises dichloromethane.

[0202] In some embodiments, the solvent component comprises methanol and dichloromethane.

[0203] In some embodiments, the method further comprises removing a majority of the dichloromethane to precipitate the salt.

[0204] In some embodiments, the method further comprises removing a majority of the dichloromethane to precipitate the salt.

[0205] In some embodiments, the method further comprises forming a solution of the compound of Formula I in a solvent component prior to said reacting.

[0206] In another embodiment, the solution is formed by heating a slurry of the compound of Formula I in the solvent component to a temperature of about 45°C to about 55°C.

[0207] In another embodiment, the method further comprises stirring the solution prior to reacting the compound of formula I with maleic acid; and filtering the solution to form a filtrate.

[0208] In another embodiment, the method further comprises adding activated carbon and silica gel to the solution after the step of heating the slurry to a temperature of about 45°C to about 55°C to form a solution and before the step of stirring the solution.

[0209] In some embodiments, the method of preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate comprises:

[0210] Adding the compound of formula I to the solvent component at room temperature to form a slurry;

[0211] heating the slurry to a temperature of about 45° C. to about 55° C. to form a solution;

[0212] stirring the solution;

[0213] filtering the solution to produce a filtrate;

[0214] adding maleic acid to the filtrate; and

[0215] The solvent is removed from the filtrate to precipitate the salt.

[0216] In some embodiments, the solvent component comprises methanol.

[0217] In some embodiments, the solvent component comprises dichloromethane.

[0218] In some embodiments, the solvent component comprises methanol and dichloromethane.

[0219] In some embodiments, the method further comprises adding activated carbon to the solution after the step of heating the slurry to a temperature of about 45°C to about 55°C to form a solution and before the step of stirring the solution.

[0220] In some embodiments, the method further comprises adding silica gel to the solution after the step of heating the slurry to a temperature of about 45°C to about 55°C to form a solution and before the step of stirring the solution.

[0221] In some embodiments, the method further comprises adding activated carbon and silica gel to the solution after the step of heating the slurry to a temperature of about 45°C to about 55°C to form a solution and before the step of stirring the solution.

[0222] Provided herein is a method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate Form II, the method comprising evaporating a saturated solution of Compound I maleate in chloroform at 25±1°C. The method for preparing the maleate Form II of the compound of Formula I is shown in Example 16, Table 10.

[0223] Provided herein is a method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate Form III, the method comprising evaporating a saturated solution of Compound I maleate in 1,4-dioxane at 25±1°C. The method for preparing the maleate Form III of the compound of Formula I is shown in Example 16, Table 10.

[0224] Provided herein is a method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate Form IV, the method comprising evaporating a saturated solution of Compound I maleate in n-BuOH at 50±1°C. The method for preparing the maleate Form IV of the compound of Formula I is shown in Example 16, Table 10.

[0225] Provided herein is a method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate Form V, the method comprising adding a saturated solution of Compound I maleate in dichloromethane to heptane and stirring. The method for preparing Formula I compound maleate Form V is shown in Example 16, Table 10.

[0226] The present application also provides a method for preparing a salt of formula II:

[0227]

[0228] Thus, provided herein is a method for preparing the salt N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate, the method comprising reacting a compound of formula II with sulfuric acid to form the salt. Methods for preparing the hemisulfate salt of the compound of formula II are found in Examples 2 and 8, Table 2.

[0229] In some embodiments, about 0.6 equivalents of sulfuric acid are used based on 1 equivalent of the compound of Formula II.

[0230] In some embodiments, the method comprises:

[0231] adding the compound of formula II to the solvent component to form a solution;

[0232] adding sulfuric acid to the solution at room temperature;

[0233] concentrating the solution to form a slurry;

[0234] Stirring the slurry at a temperature of about 60°C to about 70°C; and

[0235] The slurry is cooled to a temperature of about 15°C to about 25°C to precipitate the salt.

[0236] In some embodiments, the solvent component comprises methanol.

[0237] In some embodiments, the solvent component comprises dichloromethane.

[0238] In some embodiments, the solvent component comprises methanol and dichloromethane.

[0239] In some embodiments, the sulfuric acid is about 1 M in water.

[0240] In some embodiments, the method further comprises preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate. A method for preparing the sulfate salt of the compound of Formula II is shown in Scheme 2 and described in Example 2.

[0241] In some embodiments, a method for preparing the salt N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate comprises reacting a compound of Formula II with about 1 equivalent of sulfuric acid based on 1 equivalent of the compound of Formula II.

[0242] In some embodiments, the method of preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate comprises:

[0243] Adding the compound of formula II to the first solvent component at room temperature to form a solution;

[0244] heating the solution to a temperature of about 50°C to about 60°C;

[0245] adding sulfuric acid to the solution; and

[0246] The solvent is removed to precipitate the sulfate salt.

[0247] In some embodiments, the first solvent comprises methanol.

[0248] In some embodiments, the sulfuric acid is added as an aqueous solution.

[0249] In some embodiments, the above method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate comprises the following steps:

[0250] adding N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate to the second solvent component to form a slurry;

[0251] heating the slurry to a temperature of about 30°C to about 40°C;

[0252] stirring the slurry; and

[0253] The resulting hemisulfate salt was collected.

[0254] In some embodiments, the second solvent component comprises water.

[0255] Provided herein is a method for preparing an amorphous form of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate. The method for preparing an amorphous form of the hemisulfate salt of the compound of Formula II is shown in Scheme 1 and described in Example 2.

[0256] In some embodiments, a method of preparing an amorphous form of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate comprises the following steps:

[0257] adding N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate to the third solvent component at room temperature to form a solution;

[0258] filtering the solution;

[0259] concentrating the filtrate; and

[0260] The resulting solid was dried to obtain an amorphous hemisulfate salt.

[0261] In some embodiments, the third solvent component comprises acetone and methanol.

[0262] Provided herein is a method for preparing a salt of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide phosphate, the method comprising reacting a compound of formula II with phosphoric acid to form the salt. Methods for preparing the phosphate salt of the compound of formula II are shown in Example 8, Table 2. In some embodiments, about 1.2 equivalents of phosphoric acid are used based on 1 equivalent of the compound of formula II.

[0263] Provided herein is a method for preparing a salt of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate, the method comprising reacting a compound of formula II with maleic acid to form the salt. Methods for preparing maleate salts of compounds of formula II are described in Example 8, Table 2. In some embodiments, about 1.5 equivalents of maleic acid are used based on 1 equivalent of the compound of formula II.

[0264] Provided herein is a method for preparing a salt of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hydrochloride, the method comprising reacting a compound of formula II with hydrochloric acid to form the salt. The method for preparing the hydrochloride salt of the compound of formula II is shown in Example 8, Table 2. In some embodiments, about 1.2 equivalents of hydrochloric acid are used based on 1 equivalent of the compound of formula II.

[0265] Provided herein is a method for preparing a salt of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide salicylate, the method comprising reacting a compound of formula II with salicylic acid to form the salt. Methods for preparing salicylate salts of compounds of formula II are described in Example 8, Table 2. In some embodiments, about 1.2 equivalents of salicylic acid are used based on 1 equivalent of the compound of formula II.

[0266] Provided herein is a method for preparing a salt of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide methanesulfonate, the method comprising reacting a compound of formula II with methanesulfonic acid to form the salt. Methods for preparing methanesulfonates of compounds of formula II are described in Example 8, Table 2. In some embodiments, about 1 equivalent of methanesulfonic acid is used based on 1 equivalent of the compound of formula II.

[0267] Provided herein is a method for preparing a salt of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide ethanesulfonate, the method comprising reacting a compound of formula II with ethanesulfonic acid to form the salt. Methods for preparing ethanesulfonates of compounds of formula II are described in Example 8, Table 2. In some embodiments, about 1 equivalent of ethanesulfonic acid is used based on 1 equivalent of the compound of formula II.

[0268] It will be appreciated that certain inventive features that are described for clarity in the context of separate embodiments may also be provided in combination in a single embodiment (when the embodiments are intended to be combined as if written in multiple dependent form). Conversely, various inventive features that are described for brevity in the context of a single embodiment may also be provided individually or in any suitable subcombination.

[0269] The salts and compounds of the present invention may also include all isotopes of atoms present in the intermediates or final salts or compounds. Isotopes include those atoms having the same atomic number but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium.

[0270] In some embodiments, the compounds and salts may be found together with other substances such as water and solvents (eg, hydrates and solvates), or may be isolated.

[0271] In some embodiments, the compounds described herein or salts thereof (eg, the maleate salt of the compound of Formula I or the hemisulfate salt of the compound of Formula II) are substantially isolated.

[0272] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0273] As should be understood, compounds provided herein, including salts thereof, can be prepared using known organic synthesis techniques, and can be synthesized according to any of a number of possible synthetic pathways. The methods described herein can be monitored according to any suitable method known in the art. For example, product formation can be monitored by spectral means, such as nuclear magnetic resonance spectroscopy (e.g., 1H or 13C), infrared spectroscopy, or spectrophotometry (e.g., UV-visible light); or by chromatography, such as high performance liquid chromatography (HPLC) or thin layer chromatography (TLC) or other related techniques.

[0274] As used herein, the term "reacting" is used as known in the art and generally refers to bringing chemical reagents together in a manner that allows them to interact at the molecular level to achieve a chemical or physical transformation. In some embodiments, the reaction involves at least two reagents, wherein one or more equivalents of the second reagent are used relative to the first reagent. The reaction steps of the methods described herein can be carried out over a period of time and under conditions suitable for preparing the identified product.

[0275] The reaction of the method described herein can be carried out in a suitable solvent, which can be easily selected by a technician in the field of organic synthesis. Suitable solvents may be substantially unreactive with starting materials (reactants), intermediates or products at a temperature that is, for example, within the range of the freezing point temperature of the solvent to the boiling point temperature of the solvent. A given reaction can be carried out in a solvent or a mixture of more than one solvent. Depending on the specific reaction step, a solvent (or its mixture) suitable for use in a specific reaction step can be selected.

[0276] Suitable solvents can include halogenated solvents such as carbon tetrachloride, bromodichloromethane, dibromochloromethane, bromoform, chloroform, bromochloromethane, dibromomethane, chlorobutane, dichloromethane, tetrachloroethylene, trichloroethylene, 1,1,1-trichloroethane, 1,1,2-trichloroethane, 1,1-dichloroethane, 2-chloropropane, 1,2-dichloroethane, 1,2-dibromoethane, hexafluorobenzene, 1,2,4-trichlorobenzene, 1,2-dichlorobenzene, chlorobenzene, fluorobenzene, mixtures thereof, and the like.

[0277] Suitable ether solvents include dimethoxymethane, tetrahydrofuran, 1,3-dioxane, 1,4-dioxane, furan, diethyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, diethylene glycol diethyl ether, triethylene glycol dimethyl ether, anisole, tert-butyl methyl ether, mixtures thereof, and the like.

[0278] Suitable protic solvents may include, for example, but are not limited to, water, methanol, ethanol, 2-nitroethanol, 2-fluoroethanol, 2,2,2-trifluoroethanol, ethylene glycol, 1-propanol, 2-propanol, 2-methoxyethanol, 1-butanol, 2-butanol, isobutanol, tert-butanol, 2-ethoxyethanol, diethylene glycol, 1-pentanol, 2-pentanol or 3-pentanol, neopentyl alcohol, tert-pentanol, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, cyclohexanol, benzyl alcohol, phenol or glycerol.

[0279] Suitable aprotic solvents may include, for example, but are not limited to, tetrahydrofuran (THF), N,N-dimethylformamide (DMF), N,N-dimethylacetamide (DMA), 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone (DMPU), 1,3-dimethyl-2-imidazolidinone (DMI), N-methylpyrrolidone (NMP), formamide, N-methylacetamide, N-methylformamide, acetonitrile, dimethyl sulfoxide, propionitrile, ethyl formate, methyl acetate, hexachloroacetone, acetone, ethyl methyl ketone, ethyl acetate, sulfolane, N,N-dimethylpropionamide, tetramethylurea, nitromethane, nitrobenzene, or hexamethylphosphoramide.

[0280] Suitable hydrocarbon solvents include benzene, cyclohexane, pentane, hexane, toluene, cycloheptane, methylcyclohexane, heptane, ethylbenzene, m-, o- or p-xylene, octane, indane, nonane or naphthalene.

[0281] The reactions of the methods described herein can be carried out at appropriate temperatures, which can be readily determined by those skilled in the art. The reaction temperature will depend on factors such as the melting and boiling points of the reagents and solvents (if present); reaction thermodynamics (e.g., a violently exothermic reaction may require low temperatures); and reaction kinetics (e.g., a high activation energy barrier may require high temperatures).

[0282] The expressions "ambient temperature" and "room temperature" as used herein are understood in the art and generally refer to a temperature about the room temperature where the reaction is carried out, e.g., reaction temperature, e.g., a temperature of about 20°C to about 30°C.

[0283] The reactions of the methods described herein can be carried out in air or under an inert atmosphere. Typically, reactions containing reagents or products that are substantially reactive with air can be carried out using air-sensitive synthesis techniques well known to those skilled in the art.

[0284] How to use

[0285] The salts of the present invention (e.g., salts of compounds of formula I and salts of compounds of formula II) can modulate or inhibit the activity of TAM kinases. For example, the compounds of the present invention can be used to inhibit the activity of the kinase in the cell or in the individual or patient by administering an inhibitory amount of the compounds of the present invention to the cell, individual or patient in need of inhibiting TAM kinases.

[0286] In some embodiments, the salts of the invention are more selective for TAM kinases than one or more other kinases. In some embodiments, the compounds of the invention are more selective for TAM kinases than other kinases. In some embodiments, the selectivity is more than 2 times, more than 3 times, more than 5 times, more than 10 times, more than 25 times, more than 50 times, or more than 100 times.

[0287] The salts of the present invention may inhibit one or more of AXL, MER, and TYRO3. In some embodiments, the salt has selectivity for one TAM kinase over another. "Selectivity" means that the compound binds to or inhibits TAM kinases with greater affinity or potency, respectively, compared to a reference enzyme, such as another TAM kinase. For example, the salt may have selectivity for AXL over MER and TYRO3, selectivity for MER over AXL and TYRO3, or selectivity for AXL and MER over TYRO3. In some embodiments, the salt inhibits all TAM family members (e.g., AXL, MER, and TYRO3). In some embodiments, the salt may have selectivity for AXL and MER over TYRO3 and other kinases. In some embodiments, a method of inhibiting AXL and MER kinases is provided herein, the method comprising contacting the AXL and MER kinases with a salt provided herein or a pharmaceutically acceptable salt thereof.

[0288] As TAM kinase inhibitors, the compounds of the present invention can be used to treat various diseases related to abnormal expression or activity of TAM kinases. The salts of (Formula I and Formula II) compounds that inhibit TAM kinases will be used to provide a means of preventing tumor growth or inducing tumor cell apoptosis, specifically, by inhibiting angiogenesis. Therefore, it is expected that the salt will be proven to be useful for treating or preventing proliferative disorders, such as cancer. Specifically, tumors with receptor tyrosine kinase activation mutants or upregulated receptor tyrosine kinases may be particularly sensitive to the inhibitors.

[0289] In certain embodiments, the present invention provides a method for treating a disease or condition mediated by TAM kinase in a patient in need thereof, the method comprising the step of administering to the patient a salt provided herein (e.g., a salt of a compound of Formula I and a salt of a compound of Formula II) or a pharmaceutically acceptable composition thereof.

[0290] For example, the salts of the invention can be used to treat cancer. Example cancers include bladder cancer, breast cancer, cervical cancer, colorectal cancer, small intestine cancer, colon cancer, rectal cancer, anal cancer, endometrial cancer, gastric cancer, head and neck cancer (e.g., laryngeal cancer, hypopharyngeal cancer, nasopharyngeal cancer, oropharyngeal cancer, lip cancer, and oral cancer), kidney cancer, liver cancer (e.g., hepatocellular carcinoma, cholangiocarcinoma), lung cancer (e.g., adenocarcinoma, small cell lung cancer and non-small cell lung cancer, small cell carcinoma and non-small cell carcinoma, bronchial lung cancer, bronchial adenoma, pleuropulmonary blastoma), ovarian cancer, prostate cancer, testicular cancer, uterine cancer, esophageal cancer, gallbladder cancer, pancreatic cancer (e.g., exocrine pancreatic cancer), gastric cancer, thyroid cancer, parathyroid cancer, skin cancer (e.g., squamous cell carcinoma, Kaposi sarcoma, Merkel cell skin cancer) and brain cancer (e.g., astrocytoma, medulloblastoma, ependymoma, neuroectodermal tumor, pinealoma).

[0291] Other cancers treatable with the compounds of the invention include bone cancer, intraocular cancer, gynecological cancer, cancer of the endocrine system, adrenal cancer, soft tissue sarcomas, urethral cancer, penile cancer, pituitary cancer, triple negative breast cancer (TNBC), and environmentally induced cancers, including those induced by asbestos.

[0292] Other example cancers include hematopoietic malignancies such as leukemia or lymphoma, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, cutaneous T-cell lymphoma, acute myeloid leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma, myeloproliferative neoplasms (e.g., polycythemia vera, essential thrombocythemia, and primary myelofibrosis), Waldenstrom's Macroglubulinemia, hairy cell lymphoma, chronic myeloid lymphoma, acute lymphoblastic lymphoma, AIDS-related lymphoma, and Burkitt's lymphoma.

[0293] Other cancers that may be treated with the compounds of the invention include ocular tumors, glioblastoma, melanoma, rhabdomyosarcoma, lymphosarcoma, and osteosarcoma.

[0294] The salts of the present invention can also be used to inhibit tumor metastasis.

[0295] In some embodiments, diseases and indications treatable using the compounds of the present invention include, but are not limited to, hematological cancers, sarcomas, lung cancers, gastrointestinal cancers, genitourinary tract cancers, liver cancers, bone cancers, cancers of the nervous system, gynecological cancers, and skin cancers.

[0296] Exemplary hematological cancers include lymphomas and leukemias, such as acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), marginal zone lymphoma (MZL), non-Hodgkin's lymphoma (including relapsed or refractory NHL) , follicular lymphoma (FL), Hodgkin's lymphoma, lymphoblastic lymphoma, myeloproliferative disorders (e.g., primary myelofibrosis (PMF), polycythemia vera (PV), essential thrombocythemia (ET)), myelodysplastic syndrome (MDS), T-cell acute lymphoblastic lymphoma (T-ALL), multiple myeloma, cutaneous T-cell lymphoma, peripheral T-cell lymphoma, Waldenstrom's macroglobulinemia, hairy cell lymphoma, chronic myeloid lymphoma, and Burkitt's lymphoma.

[0297] Exemplary sarcomas include chondrosarcoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, angiosarcoma, fibrosarcoma, liposarcoma, myxoma, rhabdomyoma, rhabdomyosarcoma, fibroma, lipoma, hamartoma, and teratoma.

[0298] Exemplary lung cancers include non-small cell lung cancer (NSCLC), small cell lung cancer, bronchogenic carcinoma (squamous cell, undifferentiated small cell, undifferentiated large cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial adenoma, enchondromatous hamartoma, and mesothelioma.

[0299] Exemplary gastrointestinal cancers include esophageal cancer (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), gastric cancer (carcinoma, lymphoma, leiomyosarcoma), pancreatic cancer (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumors, vipoma), small intestine cancer (adenocarcinoma, lymphoma, carcinoid tumors, Kaposi's sarcoma, leiomyoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine cancer (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyoma), colorectal cancer, and bile duct cancer.

[0300] Exemplary genitourinary tract cancers include renal cancer (adenocarcinoma, Wilms tumor [nephroblastoma], renal cell carcinoma), bladder cancer and urinary tract cancer (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma, urothelial carcinoma), prostate cancer (adenocarcinoma, sarcoma), and testicular cancer (seminoma, teratoma, embryonal carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenomatoid tumor, lipoma).

[0301] Exemplary liver cancers include hepatoma (hepatocellular carcinoma), cholangiocarcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, and hemangioma.

[0302] Exemplary bone cancers include, e.g., osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma (reticular cell sarcoma), multiple myeloma, malignant giant cell tumor chordoma, osteochondrofibroma (osteocartilaginous exostosis), benign enchondroma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor.

[0303] Exemplary nervous system cancers include cancers of the skull (osteomas, hemangiomas, granulomas, xanthomas, osteitis deformans), meningeal cancers (meningiomas, meningosarcomas, gliomatosis), brain cancers (astrocytomas, medullocytomas, gliomas, ependymomas, germinal histoma (pinealoma), glioblastoma, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumors), and spinal cord cancers (neurofibromas, meningiomas, gliomas, sarcomas), as well as neuroblastoma, Lhermitte-Duclos disease, central nervous system (CNS) neoplasms, primary CNS lymphomas, and spinal cord tumors.

[0304] Exemplary gynecological cancers include uterine cancer (endometrial cancer), cervical cancer (cervical carcinoma, preneoplastic cervical dysplasia), ovarian cancer (ovarian carcinoma (serous cystadenocarcinoma, mucinous cystadenocarcinoma, unclassified carcinoma), granulosa-theca cell tumor, Sertoli-Leydig cell tumor, dysgerminoma, malignant teratoma), vulvar cancer (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vaginal cancer (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma (embryonal rhabdomyosarcoma), and fallopian tube cancer (carcinoma).

[0305] Exemplary skin cancers include melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Meckel cell skin cancer, nevus dysplasia, lipoma, hemangioma, dermatofibroma, and keloid.

[0306] Exemplary head and neck cancers include glioblastoma, melanoma, rhabdomyosarcoma, lymphosarcoma, osteosarcoma, squamous cell carcinoma, adenocarcinoma, oral cancer, laryngeal cancer, nasopharyngeal cancer, nasal and paranasal cancer, thyroid cancer, and parathyroid cancer.

[0307] In some embodiments, the present invention provides a method for treating hepatocellular carcinoma in a patient in need thereof, comprising the step of administering to the patient a salt of a compound of formula I or a salt of a compound of formula II, or a composition comprising a salt of a compound of formula I or a salt of a compound of formula II.

[0308] In some embodiments, the present invention provides a method for treating rhabdomyosarcoma, esophageal cancer, breast cancer, or head and neck cancer in a patient in need thereof, the method comprising the step of administering to the patient a salt of a compound of formula I or a salt of a compound of formula II, or a composition comprising a salt of a compound of formula I or a salt of a compound of formula II.

[0309] In some embodiments, the present invention provides a method of treating cancer, wherein the cancer is selected from hepatocellular carcinoma, breast cancer, bladder cancer, colorectal cancer, melanoma, mesothelioma, lung cancer, prostate cancer, pancreatic cancer, testicular cancer, thyroid cancer, squamous cell carcinoma, glioblastoma, neuroblastoma, uterine cancer and rhabdomyosarcoma.

[0310] Targeting TAM receptor tyrosine kinases can provide a therapeutic method for treating viral diseases (T Shibata et al., The Journal of Immunology, 2014, 192, 3569-3581). The present invention provides a method for treating infection, such as viral infection. The method comprises administering a therapeutically effective amount of a salt of a compound of formula I or a salt of a compound of formula II or a composition comprising a salt of a compound of formula I or a salt of a compound of formula II to a patient in need.

[0311] Examples of viruses that cause infections that can be treated by the methods of the invention include, but are not limited to, human immunodeficiency virus, human papilloma virus, influenza, hepatitis A, B, C, or D virus, adenovirus, poxvirus, herpes simplex virus, human cytomegalovirus, severe acute respiratory syndrome virus, ebola virus, Marburg virus, and measles virus. In some embodiments, viruses that cause infections that can be treated by the methods of the present invention include, but are not limited to, hepatitis (type A, B, or C), herpes viruses (e.g., VZV, HSV-1, HAV-6, HSV-II, and CMV, Epstein Barr virus), adenovirus, influenza virus, yellow fever virus (e.g., West Nile virus, dengue virus, tick-transmitted encephalitis virus, yellow fever virus, Zika virus), echovirus, rhinovirus, coxsackie virus, coronavirus, respiratory syncytial virus, mumps virus, rotavirus, measles virus, rubella virus, parvovirus, vaccinia virus, HTLV virus, dengue virus, papilloma virus, molluscum virus, polio virus, rabies virus, JC virus, and arboviral encephalitis virus.

[0312] In some embodiments, the present invention provides a method for treating thrombosis (JEM Cosemans et al., J. of Thrombosis and Haemostasis 2010, 8, 1797-1808; and A. Angelillo-Scherrer et al., J. Clin. Invest. 2008, 118, 583-596).

[0313] Combination therapy

[0314] One or more other pharmaceutical agents or treatment methods, such as antiviral agents, chemotherapeutic agents or other anticancer agents, immunopotentiators, immunosuppressants, radiation, antitumor and antiviral vaccines, cytokine therapy (e.g., IL2, GM-CSF, etc.) and / or tyrosine kinase inhibitors can be used in combination with compounds of formula (I) or as described herein for treating TAM-related diseases, disorders or conditions. The agent can be combined with a salt of the present invention (e.g., a salt of a compound of formula I and a salt of a compound of formula II) in a single dosage form, or the agent can be administered simultaneously or sequentially as a separate dosage form.

[0315] Suitable antiviral agents contemplated for use in combination with the salts of the present invention may include nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.

[0316] Examples of suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil (1592U89); dipivoxil) [bis(POM)-PMEA]; lobucavir (BMS-180194); BCH-10652; emitricitabine [(-)-FTC]; β-L-FD4 (also known as β-L-D4C and named β-L-2',3'-dideoxy-5-fluoro-cytidine); DAPD ((-)-β-D-2,6,-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione); and (+)-calendula lactone A (NSC-675451) and B. Typical suitable protease inhibitors include saquinavir (Ro 31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfnavir (AG-1343); amprenavir (141W94); lasinavir (BMS-234475); DMP-450; BMS-2322623; ABT-378; and AG-1549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside, and Isam Project No. 11607.

[0317] Agents suitable for use in combination with the salts of the present application for the treatment of cancer include chemotherapeutic agents, targeted cancer therapy, immunotherapy or radiotherapy. The salts of the present invention may be effective in combination with anti-hormonal agents for the treatment of breast cancer and other tumors. Suitable examples are anti-estrogens, including but not limited to tamoxifen and toremifene; aromatase inhibitors, including but not limited to letrozole, anastrozole and exemestane; adrenal steroids (e.g., prednisone), progesterone (e.g., megestrol acetate) and estrogen receptor antagonists (e.g., fulvestrant). Anti-hormonal agents suitable for the treatment of prostate cancer and other cancers may also be combined with the compounds of the present invention. These include anti-androgen agents, including but not limited to flutamide, bicalutamide, and nilutamide; luteinizing hormone-releasing hormone (LHRH) analogs, including leuprolide, oserelin, triptorelin, and histrelin; LHRH antagonists (e.g., degarelix); androgen receptor blockers (e.g., enzalutamide); and agents that inhibit androgen production (e.g., abiraterone).

[0318] The salt of the present invention can be combined with other agents for membrane receptor kinases or be used in order, in particular, for patients with primary or acquired resistance to targeted therapy. These therapeutic agents include inhibitors or antibodies for EGFR, Her2, VEGFR, c-Met, Ret, IGFR1, PDGFR, FGFR1, FGFR2, FGFR3, FGFR4, TrkA, TrkB, TrkC, ROS, c-Kit or Flt-3 and for cancer-related fusion protein kinases such as Bcr-Abl and EML4-Alk. Inhibitors for EGFR include gefitinib and erlotinib, and inhibitors for EGFR / Her2 include but are not limited to dacomitinib, afatinib, lapatinib and neratinib. Antibodies for EGFR include but are not limited to cetuximab, panitumumab and necitumumab. c-Met inhibitors can be used in combination with TAM inhibitors. These include onartumzumab, tivantnib and INC-280. Agents for FGFR include but are not limited to AZD4547, BAY1187982, ARQ087, BGJ398, BIBF1120, TKI258, lucitanib, dovitinib, TAS-120, JNJ-42756493 and Debio1347. Agents for Trk include but are not limited to LOXO-101 and RXDX-101. Agents directed against Abl (or Bcr-Abl) include imatinib, dasatinib, nilotinib, and ponatinib, and those directed against Alk (or EML4-ALK) include crizotinib.

[0319] The combination of angiogenesis inhibitors and TAM inhibitors may be effective in some tumors. These include antibodies or VEGFR kinase inhibitors for VEGF or VEGFR. Antibodies or other therapeutic proteins for VEGF include bevacizumab and aflibercept. VEGFR kinase inhibitors and other anti-angiogenesis inhibitors include but are not limited to sunitinib, sorafenib, axitinib, cediranib, pazopanib, regorafenib, brivanib and vandetanib.

[0320] Intracellular signaling pathway activation is frequently seen in cancer, and agents targeting components of these pathways have been combined with receptor targeting agents to enhance efficacy and reduce resistance. Examples of agents that can be combined with the compounds of the invention include PI3K-AKT-mTOR pathway inhibitors, Raf-MAPK pathway inhibitors, JAK-STAT pathway inhibitors, Pim kinase inhibitors, and protein chaperones and cell cycle progression inhibitors.

[0321] Agents for PI3 kinases include, but are not limited to, pilaralisib, idelalisib, buparlisib, and IPI-549. In some embodiments, PI3K inhibitors are selective for PI3Kα, PI3Kβ, PI3Kγ, or PI3Kδ. mTOR inhibitors, such as rapamycin, sirolimus, temsirolimus, and everolimus can be combined with TAM kinase inhibitors. Other suitable examples include, but are not limited to, vemurafenib and dabrafenib (Raf inhibitors) and trametinib, selumetinib, and GDC-0973 (MEK inhibitors). One or more JAK inhibitors (e.g., ruxolitinib, baricitinib, tofacitinib), Hsp90 inhibitors (e.g., tanespimycin), cyclin-dependent kinase inhibitors (e.g., palbociclib), PARP inhibitors (e.g., olaparib), and proteasome inhibitors (e.g., bortezomib, carfilzomib) may also be combined with the compounds of the invention. In some embodiments, the JAK inhibitor is selective for JAK1 over JAK2 and JAK3. Agents for Pim kinases include, but are not limited to, LGH447, INCB053914, and SGI-1776.

[0322] Other agents suitable for use in combination with the salts of the invention include chemotherapy combinations such as platinum-based doublets for lung cancer and other solid tumors (cisplatin or carboplatin plus gemcitabine; cisplatin or carboplatin plus docetaxel; cisplatin or carboplatin plus paclitaxel; cisplatin or carboplatin plus pemetrexed); or gemcitabine plus paclitaxel-bound particles.

[0323] Suitable chemotherapeutic or other anticancer agents include, for example, alkylating agents (including, but not limited to, nitrogen mustards, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas, and triazenes), such as uracil mustard, nitrogen mustard, cyclophosphamide (Cytoxan TM), ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphamide, busulfan, carmustine, lomustine, streptozotocin, dacarbazine, and temozolomide.

[0324] Other agents suitable for use in combination with the salts of the present invention include: dacarbazine (DTIC), optionally together with: other chemotherapy drugs, such as carmustine (BCNU) and cisplatin; "Dartmouth regimen", which consists of DTIC, BCNU, cisplatin and tamoxifen; a combination of cisplatin, vinblastine and DTIC; or temozolomide. The compounds provided herein can also be combined with immunotherapy drugs, including cytokines, such as interferon alpha, interleukin 2 and tumor necrosis factor (TNF) inhibitors.

[0325] Suitable chemotherapeutic or other anticancer agents include, for example, antimetabolites (including but not limited to folate antagonists, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.

[0326] Suitable chemotherapeutic or other anticancer agents also include, for example, certain natural products and their derivatives (e.g., vinca alkaloids, antitumor antibiotics, enzymes, lymphokines, and epipodophyllotoxins), such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, arabinoside (ara-C), paclitaxel (TAXOL TM ), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferon (especially IFN-a), etoposide and teniposide.

[0327] Other cytotoxic agents include navibene, CPT-11, anastrozole, letrozole, capecitabine, reloxafine, cyclophosphamide, ifosamide, and droloxafine.

[0328] Also suitable are cytotoxic agents such as epipodophyllotoxins; antineoplastic enzymes; topoisomerase inhibitors; procarbazine; mitoxantrone; platinum coordination complexes such as cisplatin and carboplatin; biological response modifiers; growth inhibitory agents; antihormonal therapeutics; leucovorin; tegafur; and hematopoietic growth factors.

[0329] Other anticancer agents include antibody therapeutics such as trastuzumab (Herceptin); antibodies to co-stimulatory molecules such as CTLA-4, 4-1BB, and PD-1; or antibodies to cytokines (IL-10, TGF-β, etc.).

[0330] Other anticancer agents include CSF1R inhibitors (PLX3397, LY3022855, etc.) and CSF1R antibodies (IMC-CS4, RG7155, etc.).

[0331] Other anticancer agents include BET inhibitors (INCB054329, OTX015, CPI-0610, etc.), LSD1 inhibitors (GSK2979552, INCB059872, etc.), HDAC inhibitors (panobinostat, vorinostat, etc.), DNA methyltransferase inhibitors (azacitidine and decitabine), and other epigenetic regulators.

[0332] Other anticancer agents include the Bcl2 inhibitor ABT-199 and other Bcl-2 family protein inhibitors.

[0333] Other anticancer agents include TGFβ receptor kinase inhibitors, such as LY2157299.

[0334] Other anticancer agents include BTK inhibitors such as ibrutinib.

[0335] Other anticancer agents include beta catenin pathway inhibitors, notch pathway inhibitors, and hedgehog pathway inhibitors.

[0336] Other anticancer agents include inhibitors of kinases associated with cell proliferative disorders. These kinases include, but are not limited to, Aurora-A, CDK1, CDK2, CDK3, CDK5, CDK7, CDK8, CDK9, ephrin receptor kinases, CHK1, CHK2, SRC, Yes, Fyn, Lck, Fer, Fes, Syk, Itk, Bmx, GSK3, JNK, PAK1, PAK2, PAK3, PAK4, PDK1, PKA, PKC, Rsk, and SGK.

[0337] Other anticancer agents also include those that block the migration of immune cells, such as antagonists to chemokine receptors, including CCR2 and CCR4.

[0338] Other anticancer agents also include those that enhance the immune system, such as adjuvants or adoptive T cell transfer.

[0339] Anticancer vaccines include dendritic cells, synthetic peptides, DNA vaccines, and recombinant viruses.

[0340] One or more other immune checkpoint inhibitors can be used in combination with salts as described herein for treating diseases, disorders or conditions associated with TAM.Exemplary immune checkpoint inhibitors include inhibitors for immune checkpoint molecules such as CD20, CD27, CD28, CD40, CD122, CD96, CD73, CD47, OX40, GITR, CSF1R, JAK, PI3Kδ, PI3Kγ, TAM, arginase, CD137 (also referred to as 4-1BB), ICOS, A2AR, B7-H3, B7-H4, BTLA, CTLA-4, LAG3, TIM3, VISTA, CD96, TIGIT, PD-1, PD-L1 and PD-L2.In some embodiments, immune checkpoint molecules are stimulatory checkpoint molecules selected from CD27, CD28, CD40, ICOS, OX40, GITR and CD137. In some embodiments, the immune checkpoint molecule is an inhibitory checkpoint molecule selected from A2AR, B7-H3, B7-H4, BTLA, CTLA-4, IDO, KIR, LAG3, PD-1, TIM3, CD96, TIGIT and VISTA. In some embodiments, the salt provided herein can be used in combination with one or more agents selected from KIR inhibitors, TIGIT inhibitors, LAIR1 inhibitors, CD160 inhibitors, 2B4 inhibitors and TGFRβ inhibitors.

[0341] In some embodiments, the immune checkpoint molecule inhibitor is an anti-PD1 antibody, an anti-PD-L1 antibody, or an anti-CTLA-4 antibody.

[0342] In some embodiments, the immune checkpoint molecule inhibitor is a PD-1 inhibitor, such as an anti-PD-1 monoclonal antibody. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab (also known as MK-3475), pidilizumab, SHR-1210, PDR001 or AMP-224. In some embodiments, the anti-PD-1 monoclonal antibody is nivolumab, pembrolizumab or PDR001. In some embodiments, the anti-PD1 antibody is pembrolizumab.

[0343] In some embodiments, the immune checkpoint molecule inhibitor is a PD-L1 inhibitor, such as an anti-PD-L1 monoclonal antibody. In some embodiments, the anti-PD-L1 monoclonal antibody is BMS-935559, MEDI4736, MPDL3280A (also known as RG7446), or MSB0010718C. In some embodiments, the anti-PD-L1 monoclonal antibody is MPDL3280A (atezolizumab) or MEDI4736 (durvalumab).

[0344] In some embodiments, the immune checkpoint molecule inhibitor is a CTLA-4 inhibitor, such as an anti-CTLA-4 antibody. In some embodiments, the anti-CTLA-4 antibody is ipilimumab or tremelimumab.

[0345] In some embodiments, the immune checkpoint molecule inhibitor is a LAG3 inhibitor, such as an anti-LAG3 antibody. In some embodiments, the anti-LAG3 antibody is BMS-986016 or LAG525.

[0346] In some embodiments, the immune checkpoint molecule inhibitor is a GITR inhibitor, such as an anti-GITR antibody. In some embodiments, the anti-GITR antibody is TRX518, MK-4166, INCAGN01876 or MK-1248.

[0347] In some embodiments, the immune checkpoint molecule inhibitor is an OX40 inhibitor, such as an anti-OX40 antibody or an OX40L fusion protein. In some embodiments, the anti-OX40 antibody is MEDI0562, INCAGN01949, GSK2831781, GSK-3174998, MOXR-0916, PF-04518600, or LAG525. In some embodiments, the OX40L fusion protein is MEDI6383.

[0348] In some embodiments, the immune checkpoint molecule inhibitor is a CD20 inhibitor, such as an anti-CD20 antibody. In some embodiments, the anti-CD20 antibody is obinutuzumab or rituximab.

[0349] The salts of the present invention can be used in combination with bispecific antibodies. In some embodiments, one of the domains of the bispecific antibody targets PD-1, PD-L1, CTLA-4, GITR, OX40, TIM3, LAG3, CD137, ICOS, CD3 or TGFβ receptor.

[0350] The salt of the present invention can be used in combination with one or more agents for treating diseases such as cancer. In some embodiments, the agent is an alkylating agent, a proteasome inhibitor, a corticosteroid or an immunomodulator. Examples of alkylating agents include cyclophosphamide (CY), melphalan (MEL) and bendamustine. In some embodiments, the proteasome inhibitor is carfilzomib. In some embodiments, the corticosteroid is dexamethasone (DEX). In some embodiments, the immunomodulator is lenalidomide (LEN) or pomalidomide (POM).

[0351] The salt of the present invention can be combined with another immunogenic agent, such as cancer cells, purified tumor antigens (including recombinant proteins, peptides and carbohydrate molecules), cells and cells transfected with genes encoding immunostimulatory cytokines. Non-limiting examples of tumor vaccines that can be used include peptides of melanoma antigens, such as gp100, MAGE antigens, Trp-2, MARTI and / or tyrosinase, or tumor cells transfected to express the cytokine GM-CSF.

[0352] The salts of the present invention can be used in combination with vaccination regimens to treat cancer. In some embodiments, tumor cells are transduced to express GM-CSF. In some embodiments, tumor vaccines include proteins from viruses implicated in human cancers, such as human papillomavirus (HPV), hepatitis viruses (HBV and HCV), and Kaposi's herpes sarcoma virus (KHSV). In some embodiments, the salts of the present invention can be used in combination with tumor-specific antigens, such as heat shock proteins isolated from tumor tissue itself. In some embodiments, the salts of the present invention can be combined with dendritic cell immunization to activate an effective anti-tumor response.

[0353] The salts of the invention can be combined with bispecific macrocyclic peptides that target effector cells expressing Fcα or Fcγ receptors to tumor cells. The salts of the invention can also be combined with macrocyclic peptides that activate the host immune response.

[0354] The salts of the invention may be used in combination with an arginase inhibitor, such as CB-1158.

[0355] The salts of the present invention can be used in combination with one or more metabolic enzyme inhibitors. In some embodiments, the metabolic enzyme inhibitor is an IDO1 inhibitor, a TDO inhibitor or an arginase inhibitor. Examples of IDO1 inhibitors include epacadostat and NGL919.

[0356] The salts of the present invention can be used in combination with bone marrow transplantation to treat a variety of hematopoietic tumors.

[0357] The salts of the present invention can be used as anticoagulants, either as a single agent or in combination with other anticoagulants, including but not limited to apixaban, dabigatran, edoxaban, fondaparinex, heparin, rivaroxaban, and warfarin.

[0358] The methods of safely and effectively using most of these chemotherapeutics are known to those skilled in the art. In addition, their use is described in standard literature. For example, many of the chemotherapeutics are described in the "Physicians' Desk Reference" (PDR, e.g., 1996 edition, Medical Economics Company, Montvale, NJ), the disclosure of which is incorporated herein by reference, as described in full.

[0359] Drug preparations and dosage forms

[0360] When used as a drug, the salt provided herein can be administered in the form of a pharmaceutical composition, which refers to a combination of a compound provided herein or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable carrier. These compositions can be prepared in a manner well known in pharmaceutical technology and can be administered by a variety of routes, depending on whether local treatment or systemic treatment is required and the area to be treated. Administration can be local (including ocular and application to mucous membranes, including intranasal, vaginal and rectal delivery), pulmonary (e.g., by inhalation or insufflation of powders or aerosols, including by nebulizers; intratracheal, intranasal, epidermal and transdermal), ocular, oral or parenteral. The method of ocular delivery can include topical administration (eye drops), subconjunctival, periocular or intravitreal injection, or introduction by surgical placement of a balloon catheter or eye insert in the conjunctival sac. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial (e.g., intrathecal) or intraventricular administration. Parenteral administration can be in the form of a single bolus dose, or can be, for example, by a continuous infusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous solutions, powders or oily bases, thickeners and the like may be necessary or desirable.

[0361] The application also includes many pharmaceutical compositions, which contain a combination of one or more salts provided herein (e.g., salts of compounds of formula I and compounds of formula II) as active ingredients and one or more pharmaceutically acceptable carriers. When manufacturing the composition of the present invention, the active ingredient is typically mixed with an excipient, diluted or encapsulated in such carriers in the form of capsules, sachets, paper or other containers by an excipient. When an excipient acts as a diluent, it can be a solid, semisolid or liquid material, thereby acting as a vehicle, carrier or medium of the active ingredient. Therefore, the composition can be in the form of lozenges, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (in solid form or in liquid media), ointments containing, for example, up to 10% by weight of active compounds, soft capsules and hard capsules, suppositories, sterile injectable solutions, and sterile packaged powders.

[0362] When preparing a formulation, the active compound (or salt form of the present invention) can be ground to provide an appropriate particle size and then combined with other ingredients. If the active compound is substantially insoluble, it can be ground to a particle size of less than 200 mesh. If the active compound is substantially soluble in water, the particle size can be adjusted by grinding to provide a substantially uniform distribution in the formulation, such as about 40 mesh.

[0363] Some examples of suitable excipients include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methylcellulose. The formulation may additionally include: lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl benzoate and propyl hydroxybenzoate; and sweeteners and flavoring agents. The compositions of the present invention may be formulated to provide rapid, sustained or delayed release of the active ingredient after administration to a patient using procedures known in the art.

[0364] The compositions can be formulated in unit dosage form, each dose containing from about 5 to about 100 mg, more usually from about 10 to about 30 mg, of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable for use in unit dosage form for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in combination with a suitable pharmaceutical excipient.

[0365] The active compound can be effective within a wide dosage range and is generally administered in a therapeutically effective amount. However, it should be understood that the actual amount of compound administered will generally be determined by a physician based on relevant circumstances (including the condition to be treated, the selected route of administration, the actual compound administered, the age, weight and response of the individual patient, the severity of the patient's symptoms, etc.).

[0366] In order to prepare solid compositions such as lozenges, the main active ingredient is mixed with a pharmaceutical excipient to form a solid preformulated composition containing a homogeneous mixture of the compounds of the invention. When these preformulated compositions are mentioned to be homogeneous, the active ingredient is typically evenly dispersed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms, such as lozenges, pills and capsules. This solid preformulation is then subdivided into unit dosage forms belonging to the above-described type containing, for example, about 0.1 to about 500 mg of the active ingredient of the invention.

[0367] The tablets or pills of the present invention can be coated or otherwise mixed to provide a dosage form that can obtain the advantage of extended time of action. For example, tablets or pills can include an inner dose and an outer dose component, the latter being in the form of an envelope on the former. The two components can be separated by an enteric coating layer, which is used to resist disintegration in the stomach and allow the inner component to enter the duodenum intact or delay release. A variety of materials can be used for such enteric coating layers or coating layers, including many polymeric acids and mixtures of polymeric acids with materials such as shellac, cetyl alcohol and cellulose acetate.

[0368] Liquid forms that may be incorporated into the salts and compositions of the invention for oral or injection administration include aqueous solutions, appropriately flavored syrups, aqueous or oil suspensions and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

[0369] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof, and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. In some embodiments, the composition is administered by oral or nasal respiratory route to achieve local or systemic effects. The composition may be atomized using an inert gas. The atomized solution may be breathed directly from the atomizing device, or the atomizing device may be connected to a mask curtain or an intermittent positive pressure breathing machine. The solution, suspension or powder composition may be administered orally or nasally from a device that delivers the formulation in an appropriate manner.

[0370] The amount of salt (e.g., salt of a compound of formula I and salt of a compound of formula II) or composition administered to a patient will depend on what is administered, the purpose of administration (such as prevention or treatment), the patient's state, the mode of administration, and the like. In therapeutic applications, the amount of the composition that can be administered to a patient already suffering from a disease is sufficient to cure or at least partially arrest the symptoms of the disease and its complications. The effective dose will depend on the disease condition being treated and the judgment made by the attending physician based on factors such as the severity of the disease, the patient's age, weight, and general condition, and the like.

[0371] The composition administered to the patient can be in the form of the pharmaceutical composition described above. These compositions can be sterilized by conventional sterilization techniques, or can be aseptically filtered. The aqueous solution can be packaged for use as is, or lyophilized, and the lyophilized preparation can be combined with a sterile aqueous carrier before administration. The pH of the compound preparation will typically be between 3 and 11, more preferably 5 to 9 and most preferably 7 to 8. It should be understood that the use of some of the aforementioned excipients, carriers or stabilizers will form a pharmaceutical salt.

[0372] The therapeutic dose of the compounds or salts of the present invention can vary according to, for example, the specific use for treatment, the mode of administration of the compound, the health status of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compounds or salts provided herein in the pharmaceutical composition may vary depending on many factors, including dosage, chemical characteristics (e.g., hydrophobicity), and route of administration. For example, the compounds or salts provided herein may be provided in the form of aqueous physiological buffer solutions containing about 0.1% to about 10% w / v compounds or salts for parenteral administration. Some typical dosage ranges are about 1 μg / kg to about 1 g / kg body weight per day. In some embodiments, the dosage range is about 0.01 mg / kg to about 100 mg / kg body weight per day. The dosage may depend on variables such as the type and degree of progression of the disease or condition, the overall health status of a particular patient, the relative biological efficacy of the selected compound, the formulation of the excipient, and its route of administration. The effective dose can be extrapolated from a dose response curve obtained from an in vitro or animal model test system.

[0373] The compounds or salts provided herein can also be formulated in combination with one or more other active ingredients, which can include any pharmaceutical agent, such as an antiviral agent, a vaccine, an antibody, an immunopotentiator, an immunosuppressant, an anti-inflammatory agent, and the like.

[0374] Pill Box

[0375] The present invention also includes a kit that can be used, for example, to treat or prevent TAM-related diseases or disorders, obesity, diabetes, and other diseases mentioned herein, the kit comprising one or more containers containing a pharmaceutical composition comprising a therapeutically effective amount of a salt provided herein (e.g., a salt of a compound of Formula I and a salt of a compound of Formula II). As should be apparent to those skilled in the art, the kit may also include one or more of a variety of conventional kit components as needed, such as a container containing one or more pharmaceutically acceptable carriers, an additional container, and the like. The kit may also include instructions in the form of an insert or a label, indicating the amount of the component to be administered, instructions on administration, and / or instructions on mixing the components.

[0376] Example

[0377] The present invention will be described in more detail by specific examples. The following examples are provided for illustrative purposes and are not intended to limit the present invention in any way. One skilled in the art should readily recognize multiple non-critical parameters that can be changed or modified to produce substantially the same results. The compounds found in the examples are TAM kinase inhibitors as described below.

[0378] General approach

[0379] Preparative LC-MS purification of some of the compounds prepared was performed on a Waters mass directed fractionation system. The basic equipment setup, protocols and control software used to operate these systems have been described in detail in the literature. See, for example, "Two-Pump At Column Dilution Configuration for Preparative LC-MS", K. Blom, J. Combi. Chem., 4, 295 (2002); "Optimizing Preparative LC-MS Configurations and Methods for Parallel Synthesis" Purification", K. Blom, R. Sparks, J. Doughty, G. Everlof, T. Haque, A. Combs, J. Combi. Chem., 5, 670 (2003); and "Preparative LC-MSPurification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Combi. Chem., 6, 874-883 (2004). Analytical liquid chromatography mass spectrometry (LCMS) was typically performed on the isolated compounds under the following conditions for purity verification: Instrument: Agilent 1100 series, LC / MSD; Column: Waters Sunfire TM C 18 5 μm particle size, 2.1 x 5.0 mm; buffer: mobile phase A: 0.025% TFA / water, and mobile phase B: acetonitrile; gradient: 2% to 80% B, 3 minutes, flow rate 2.0 mL / min.

[0380] Some of the prepared compounds were also separated on a preparative scale by reverse phase high performance liquid chromatography (RP-HPLC) or flash chromatography (silica gel) with MS detection as indicated in the Examples. Typical preparative reverse phase high performance liquid chromatography (RP-HPLC) column conditions were as follows:

[0381] pH = 2 Purification: Waters Sunfire TM C 185 μm particle size, 19×100 mm column, eluted with mobile phase A: 0.1% TFA (trifluoroacetic acid) / water and mobile phase B: acetonitrile; the flow rate was 30 mL / min, and the separation gradient of each compound was optimized using the Compound Specific Method Optimization protocol as described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate for a 30×100 mm column is 60 mL / min.

[0382] pH = 10 Purification: Waters XBridge C 18 5 μm particle size, 19×100 mm column, eluted with mobile phase A: 0.15% NH4OH / water and mobile phase B: acetonitrile; the flow rate was 30 mL / min, and the separation gradient of each compound was optimized using the compound-specific method optimization scheme described in the literature [see "Preparative LCMS Purification: Improved Compound Specific Method Optimization", K. Blom, B. Glass, R. Sparks, A. Combs, J. Comb. Chem., 6, 874-883 (2004)]. Typically, the flow rate for a 30×100 mm column is 60 mL / min.

[0383] Example 1. Synthesis of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (Compound I maleate, Form I)

[0384] Process 1.

[0385]

[0386] Step 1. 5-Bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-4-amine dihydrochloride (Compound 2)

[0387] At room temperature, a 5-neck 22L round-bottom flask equipped with a mechanical stirrer, a heating mantle, a thermocouple, a reflux condenser, a nitrogen inlet and a nitrogen outlet was placed in dichloromethane (DCM, 8.0L) containing tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine-7-yl)piperidine-1-carboxylate (Compound 1, 880g, 2.221mol). 2-Propanol (5.8N, 2.7L, 15.66mol, 7.05 equivalents) containing hydrochloric acid was added to the suspension. The mixture was heated to 35°C. After 4 hours, the reaction mixture was diluted with tert-butyl methyl ether (TBME, 4.5L). The resulting mixture was cooled to room temperature, filtered and washed with TBME (2.0L). The filter cake was dried on the filter under house vacuum for 24 hours to afford 5-bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-4-amine dihydrochloride (Compound 2, 848 g, 103%) as a light brown solid. 1 H NMR (400MHz, DMSO-d6) δ9.53-9.29(m,3H),8.23(s,1H),6.91(s,1H),3.38(tt,J=11.8,3.6Hz,1H),3.30(d ,J=12.4Hz,2H),3.00(dtd,J=12.8,10.1,2.6Hz,2H),2.07(dd,J=14.1,3.8Hz,2H),1.97-1.87(m,2H)ppm; 13 C NMR (101MHz, DMSO-d6) δ150.34,139.32,138.92,113.24,109.67,95.70,43.06,30.57,26.89ppm; C 11 H 14 BrN5(MW 295.0), LCMS(EI)m / e 296.0(M + +H).

[0388] Step 2. 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 3).

[0389] At room temperature, N-methylpiperidone (NMP, 10 L) containing 5-bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-4-amine dihydrochloride (Compound 2, 1300 g, 3.522 mol) was placed in a 5-neck 22 L round-bottom flask equipped with a mechanical stirrer, a thermocouple, a reflux condenser, a nitrogen inlet, and a nitrogen outlet. N,N-diisopropylethylamine (1593 g, 12.3 mol) was added to the suspension. The mixture was cooled to 10 ° C and then charged with isobutyryl chloride (388 g, 3.645 mol). The reactants were stirred at room temperature and monitored by HPLC. Additional isobutyryl chloride (22.5 g, 0.211 mol) was added to consume all the starting material. Once the reaction was complete, the reaction mixture was filtered through a celite pad. The resulting filtrate was cooled to 10 ° C and water (26 L) was gradually added to precipitate the product. The solids were collected by filtration and washed with water (12 L). The filter cake was dried on the filter under house vacuum for 48 hours to afford 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 3, 1095 g, 85%) as a light brown solid. 1 H NMR (400MHz, DMSO-d6) δ7.86(s,1H),6.64(s,1H),4.51(d,J=12.6Hz,1H),4.01(d,J=13.2Hz,1H),3.35-3.30(m,1H),3.12(t,J=12.3Hz ,1H),2.91-2.84(m,1H),2.64(t,J=12.1Hz,1H),2.02-1.93(m,2H),1.55-1.42(m,2H),1.02(d,J=6.5Hz,3H),1.00(d,J=6.5Hz,3H)ppm; 13 C 15 H 20 BrN5O(MW 365.09), LCMS(EI)m / e366.1(M + +H).

[0390] Step 3. 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 5).

[0391] A 5-neck 22 L round-bottom flask equipped with a mechanical stirrer, a heating mantle, a thermocouple, a reflux condenser, a nitrogen inlet and a nitrogen outlet was charged with 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 3, 700 g, 1.911 mol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (compound 4, 502 g, 2.293 mol) and potassium carbonate (528 g, 3.822 mol) in 1-butanol (7.7 L) and water (1.4 L) at room temperature. Chloro (2-dicyclohexylphosphino-2', 4', 6'-triisopropyl-1, 1'-biphenyl) [2- (2'-amino-1, 1'-biphenyl)] palladium (II) (XPhos Pd G2, 90g, 115mmol) was added to the mixture at room temperature. The reaction mixture was degassed and refilled with nitrogen, and then heated to 80°C. After two hours at 80°C, n-heptane (8L) was added to the reaction mixture. The resulting slurry was cooled to room temperature. Solids were collected by filtration and washed with water (6L). On the filter, the filter cake was dried under house vacuum for 72 hours to obtain 1- (4- (4-amino-5- (4-aminophenyl) pyrrolo [1, 2-f] [1, 2, 4] triazine -7- base) piperidin-1-yl) -2-methylpropan-1-one (compound 5, 648g, 90%) as a brown solid. 1 H NMR(500MHz,DMSO-d6)δ7.85(s,1H),7.09(d,J=8.4Hz,2H),6.65(d,J=8.4Hz,2H),6.4 3(s,1H),5.24(s,2H),4.53(d,J=12.6Hz,1H),4.04(d,J=13.1Hz,1H),3.38(ddd,J=11 .8,8.2,3.8Hz,1H),3.16(t,J=12.7Hz,1H),2.87(p,J=6.7Hz,1H),2.71-2.66(m,1H), 2.08-2.00(m,2H),1.61-1.58(m,2H),1.02(d,J=6.5Hz,3H),1.00(d,J=6.5Hz,3H)ppm; 13 C NMR (126MHz, DMSO-d6) δ174.51,156.31,148.51,147.65,133.98,130.35,122.57,119.3 7,114.57,109.67,108.85,45.48,41.81,32.97,31.50,30.56,29.50,20.06,19.89ppm; C 21H 26 N6O(MW 378.48), LCMS(EI)m / e 379.2(M + +H).

[0392] Step 4. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I).

[0393] At room temperature, tetrahydrofuran (THF, 10 L) containing 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazine-7-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 5, 944 g, 2.494 mol) and 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid hydrochloride (Compound 6, 801 g, 2.569 mol) was placed in a 5-neck 22 L round-bottom flask equipped with a mechanical stirrer, a thermocouple, a nitrogen inlet and a nitrogen outlet. Triethylamine (NEt3, 0.695 L, 4.988 mol) was added to the reaction mixture. After the reaction was completed, the reaction mixture was divided equally into two 22 L round-bottom flasks. Water (8 L) was charged to each flask at room temperature. The solid was collected by filtration. The obtained wet cake is put back into a 22L round-bottom flask. THF (3.2L) and water (10.5L) are loaded into the flask. The slurry is heated to 55 ° C and stirred for two hours at 55 ° C. Solids are collected by filtration at 30 ° C and washed with water (8L). On the filter, the filter cake is dried for 72 hours under house vacuum to obtain N- (4- (4- amino -7- (1- isobutyryl piperidine -4- bases) pyrrolo [1,2-f] [1,2,4] triazine -5- bases) phenyl) -1- isopropyl -2,4- dioxo -3- (pyridin -2- bases) -1,2,3,4- tetrahydropyrimidine -5- carboxamide (Compound I, 1425g, 90%) as a light brown solid. 1H NMR (500MHz, DMSO-d6) δ10.82(s,1H),8.71(s,1H),8.64(ddd,J=4.8,1.8,0.8Hz,1H),8.06(td,J=7.7,1.9Hz,1H),7.91(s,1H),7.7 7(d,J=8.6Hz,2H),7.60-7.53(m,2H),7.43(d,J=8.6Hz,2H),6.58(s,1H),4.78(hept,J=6.8Hz,1H),4.54(d,J=12.3Hz,1H),4.06(d, J=12.5Hz,1H),3.40(tt,J=11.7,3.5Hz,1H),3.20(t,J=12.3Hz,1H),2.91(hept,J=6.7Hz,1H),2.69(t,J=12.3Hz,1H),2.06(dd,J=2 7.7,12.3Hz,2H),1.61(q,J=11.8Hz,1H),1.55-1.47(m,1H),1.44(d,J=6.8Hz,6H),1.02(d,J=6.8Hz,3H),1.00(d,J=6.8Hz,3H)ppm; 13 C NMR(126MHz,DMSO-d6)δ174.51,163.02,160.31,156.20,150.18,149.98,149.18,148.08,147.79,139.55,137.51,134.45,131.24,130.23,1 25.09,124.57,120.46,117.98,109.90,109.35,105.27,51.17,45.46 ,41.79,32.97,31.48,30.54,29.49,21.09(2-CH3),20.07,19.89ppm; C 34 H 37 N9O4(MW635.73), LCMS(EI)m / e 636.3(M + +H).

[0394] Step 5. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (Compound I maleate, Form I).

[0395] At room temperature, methanol (MeOH, 10 L) and dichloromethane (DCM, 20 L) containing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound I, 1401 g, 2.204 mol) were placed in a 50 L reactor equipped with a mechanical stirrer, a heating jacket, a thermocouple, a reflux condenser, a nitrogen inlet, and a nitrogen outlet. The slurry was heated to 50 ° C to obtain a solution. Activated carbon (70 g) and silica gel (70 g) were added to the solution. After stirring at 50 ° C for 2 hours, the mixture was filtered through a celite pad. Maleic acid (269 g, 2.314 mol) was added to the filtrate. Most of DCM was distilled out at atmospheric pressure. Solid was gradually precipitated. Solid was collected by filtration at 18 ° C and washed with MeOH (3L). On the filter, the filter cake was dried for 72 hours under house vacuum to obtain N- (4- (4-amino -7- (1- isobutyryl piperidine -4- base) pyrrolo [1,2-f] [1,2,4] triazine -5- base) phenyl) -1- isopropyl -2,4- dioxo -3- (pyridin -2- base) -1,2,3,4- tetrahydropyrimidine -5- formamide maleate (Compound I maleate, 1425g, 86%) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ10.83(s,1H),8.71(s,1H),8.65-8.63(m,1H),8.06(td,J=7.8,1.9Hz,1H),7.95(s,1H),7.77(d,J=8.6 Hz,2H),7.58-7.55(m,2H),7.44(d,J=8.5Hz,2H),6.62(s,1H),6.25(s,2H),4.78(hept,J=6.7Hz,1H),4.54(d,J=12.3Hz,1H),4 .06(d,J=12.5Hz,1H),3.40(tt,J=11.6,3.2Hz,1H),3.20(t,J=12.3Hz,1H),2.90(hept,J=6.6Hz,1H),2.69(t,J=12.1Hz,1H),2 .09-2.01(m,2H),1.65-1.57(m,1H),1.56-1.49(m,1H),1.44(d,J=6.8Hz,6H),1.02(d,J=5.5Hz,3H),1.00(d,J=5.5Hz,3H)ppm; 13C NMR(101MHz,DMSO)δ174.52,167.21,163.03,160.33,155.20,150.18,149 .99,149.18,148.07,146.26,139.55,137.67,135.32,131.34,130.87,13 0.22,125.09,124.57,120.49,119.30,109.80,109.47,105.26,51.17,45 .43,41.76,32.97,31.45,30.53,29.50,21.09(2-CH3),20.06,19.89ppm; C 34 H 37 N9O4 (free base, MW 635.73), LCMS (EI) m / e 636.3 (M + +H).

[0396] Example 2. Synthesis of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (amorphous) (Compound II hemisulfate)

[0397] Process 2

[0398]

[0399] Step 1. 5-Bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-4-amine dihydrochloride (Compound 2)

[0400] At room temperature, a 5-neck 22L round-bottom flask equipped with a mechanical stirrer, a heating jacket, a thermocouple, a reflux condenser, a nitrogen inlet and a nitrogen outlet was charged with dichloromethane (DCM, 8.0L) containing tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazine-7-yl)piperidine-1-carboxylate (Compound 1, 880g, 2.221mol). 2-Propanol (5.8N, 2.7L, 15.66mol, 7.05 equivalents) containing hydrochloric acid was added to the suspension. The mixture was heated to 35°C and maintained for 4 hours. The reaction mixture was diluted with tert-butyl methyl ether (TBME, 4.5L) and cooled to room temperature. The slurry was filtered and washed with TBME (2.0L). The filter cake was dried on the filter under vacuum for 24 hours to afford 5-bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-4-amine dihydrochloride (Compound 2, 848 g, 103%) as a light brown solid. 1H NMR (400MHz, DMSO-d6) δ9.53-9.29(m,3H),8.23(s,1H),6.91(s,1H),3.38(tt,J=11.8,3.6Hz,1H),3.30(d ,J=12.4Hz,2H),3.00(dtd,J=12.8,10.1,2.6Hz,2H),2.07(dd,J=14.1,3.8Hz,2H),1.97-1.87(m,2H)ppm; 13 CNMR(101MHz,DMSO-d6)δ150.34,139.32,138.92,113.24,109.67,95.70,43.06,30.57,26.89ppm; C 11 H 14 BrN5(MW 295.0), LCMS(EI)m / e 296.0(M + +H).

[0401] Step 2. 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 3).

[0402] A 5-neck 22 L round bottom flask equipped with a mechanical stirrer, a thermocouple, a reflux condenser, a nitrogen inlet and a nitrogen outlet was charged with N-methylpiperidone (NMP, 10 L) containing 5-bromo-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-4-amine dihydrochloride (Compound 2, 1300 g, 3.522 mol) at room temperature. N,N-diisopropylethylamine (1593 g, 12.3 mol) was added to the suspension. The mixture was cooled to 10 ° C. and treated with isobutyryl chloride (388 g, 3.645 mol). The reaction mixture was stirred while warming to room temperature and monitored by HPLC. Additional isobutyryl chloride (22.5 g, 0.211 mol) was added to consume all the starting material. Once the reaction was complete, the reaction mixture was filtered through a celite pad. The resulting filtrate was cooled to 10 ° C and water (26 L) was gradually added to precipitate the product. The solid was collected by filtration and washed with water (12 L). The filter cake was dried under vacuum on the filter for 48 hours to obtain 1- (4- (4-amino-5-bromopyrrolo [1,2-f] [1,2,4] triazine-7-yl) piperidin-1-yl) -2-methylpropan-1-one (compound 3, 1095 g, 85%) as a light brown solid. 1H NMR (400MHz, DMSO-d6) δ7.86(s,1H),6.64(s,1H),4.51(d,J=12.6Hz,1H),4.01(d,J=13.2Hz,1H),3.35-3.30(m,1H),3.12(t,J=12.3Hz ,1H),2.91-2.84(m,1H),2.64(t,J=12.1Hz,1H),2.02-1.93(m,2H),1.55-1.42(m,2H),1.02(d,J=6.5Hz,3H),1.00(d,J=6.5Hz,3H)ppm; 13 C NMR (101MHz, DMSO-d6) δ174.50,155.68,148.37,135.22,111.36,110.65,87.27,45.34,41.67,32.91,31.30,30.33,29.49,20.03,19.87ppm; C 15 H 20 BrN5O(MW 365.09), LCMS(EI)m / e 366.1(M + +H).

[0403] Step 3. 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 5).

[0404] A 5-neck 22 L round-bottom flask equipped with a mechanical stirrer, a heating mantle, a thermocouple, a reflux condenser, a nitrogen inlet and a nitrogen outlet was charged with 1-(4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 3, 700 g, 1.911 mol), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (compound 4, 502 g, 2.293 mol) and potassium carbonate (528 g, 3.822 mol) in 1-butanol (7.7 L) and water (1.4 L) at room temperature. The mixture was treated with chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2, 90g, 115mmol) at room temperature. The reaction mixture was degassed and refilled with nitrogen, and then heated to 80°C. After two hours at 80°C, the reaction mixture was diluted with n-heptane (8L). The resulting slurry was cooled to room temperature. Solids were collected by filtration and washed with water (6L). On the filter, the filter cake was dried under vacuum for 72 hours to obtain 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazine-7-yl)piperidin-1-yl)-2-methylpropan-1-one (Compound 5, 648g, 90%) as a brown solid. 1 H NMR(500MHz,DMSO-d6)δ7.85(s,1H),7.09(d,J=8.4Hz,2H),6.65(d,J=8.4Hz,2H),6.4 3(s,1H),5.24(s,2H),4.53(d,J=12.6Hz,1H),4.04(d,J=13.1Hz,1H),3.38(ddd,J=11 .8,8.2,3.8Hz,1H),3.16(t,J=12.7Hz,1H),2.87(p,J=6.7Hz,1H),2.71-2.66(m,1H), 2.08-2.00(m,2H),1.61-1.58(m,2H),1.02(d,J=6.5Hz,3H),1.00(d,J=6.5Hz,3H)ppm; 13 C NMR (126MHz, DMSO-d6) δ174.51,156.31,148.51,147.65,133.98,130.35,122.57,119.3 7,114.57,109.67,108.85,45.48,41.81,32.97,31.50,30.56,29.50,20.06,19.89ppm; C 21 H 26N6O(MW 378.48), LCMS(EI)m / e 379.2(M + +H).

[0405] Step 4. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound II).

[0406] A 5-neck 22 L round-bottom flask equipped with a mechanical stirrer, a thermocouple, a nitrogen inlet and a nitrogen outlet was charged with 1-(4-(4-amino-5-(4-aminophenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidin-1-yl)-2-methylpropan-1-one (compound 5, 450 g, 1.189 mol) and 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (compound 7, 342 g, 1.248 mol) in tetrahydrofuran (THF, 5 L) at room temperature. The reaction mixture was treated sequentially with triethylamine (NEt3, 241 g, 2.378 mol) and then 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisourea hexafluorophosphate (V) (HATU, 565 g, 1.486 mol). After completion of the reaction, water (8 L) was added to the reaction mixture at room temperature. Solids were collected by filtration. The resulting wet cake was placed back in a 22 L round bottom flask and formed into a slurry with THF (2.7 L) and water (5.4 L). The slurry was heated to 55 ° C and stirred at 55 ° C for two hours. The solids were collected by filtration after cooling to 30 ° C and washed with water (8 L). The filter cake was dried on the filter under vacuum for 2 days to afford N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound II, 717 g, 95%) as a light brown solid. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.68(s,1H),8.19(s,1H),7.82(d,J=8.6Hz,2H),7.55-7.46(m,5H),7.38-7.36(m ,2H),6.85(s,1H),4.79(hept,J=6.8Hz,1H),4.55(d,J=12.3Hz,1H),4.08(d,J=12.9Hz,1H),3.43(tt,J=11.8,3.5Hz,1 H),3.21(t,J=12.4Hz,1H),2.90(hept,J=6.7Hz,1H),2.70(t,J=12.2Hz,1H),2.02(dd,J=23.0,13.5Hz,2H),1.66(q,J= 11.8,11.3Hz,1H),1.53(q,J=12.2,11.7Hz,1H),1.44(d,J=6.8Hz,6H),1.03(d,J=7.0Hz,3H),1.01(d,J=7.0Hz,3H)ppm; 13 C NMR (126MHz, DMSO-d6) δ174.55,163.26,160.65,152.60,150.48,147.46,142.27,138.14,137.56,135.87,130.21,129.89,129.50,129. C 35 H 38 N8O4(MW634.74), LCMS(EI)m / e 635.3(M + +H).

[0407] Step 5. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate (Compound II sulfate).

[0408] A 5-neck 22L round-bottom flask equipped with a mechanical stirrer, a thermocouple, a nitrogen inlet and a nitrogen outlet was charged with methanol (MeOH, 5.6L) containing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound II, 713g, 1.123mol) at room temperature. The mixture was heated to 55°C and treated with a solution of sulfuric acid (H2SO4, 116g, 1.179mol) in water (1L). After stirring at 55°C for 30 minutes, 2.8L of solvent was distilled off under reduced pressure. The reaction mixture was cooled to room temperature. The resulting solid was collected by filtration and washed with MeOH (0.7L). The filter cake was dried on the filter under vacuum for 2 days to afford N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate (Compound II sulfate, 744 g, 90%) as a yellow solid.

[0409] Step 6. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (Compound II hemisulfate).

[0410] A 5-neck 22L round-bottom flask equipped with a mechanical stirrer, a thermocouple, a nitrogen inlet, and a nitrogen outlet was charged with water (16L) containing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate (sulfate salt of Compound II, 729g, 0.995mol) at room temperature. The slurry was heated to 35°C and stirred for 3 days. The solid was collected by filtration and washed with water (10L). The wet cake was dried on the filter under vacuum to afford N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (Compound II hemisulfate, 644 g, 95%) as an off-white solid.

[0411] Step 7. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate, amorphous.

[0412] At room temperature, a 2-L round-bottom flask was charged with acetone (500 mL) and methanol (500 mL) containing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (Compound II hemisulfate, 40 g, 58.5 mmol). The solution was filtered through filter paper into a 3L single-necked round-bottom flask. The filtrate was concentrated under reduced pressure to remove most of the solvent. The foamy solid was dried in a vacuum oven at 50 °C under house vacuum and nitrogen purge to give N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate (amorphous hemisulfate of Compound II, 38 g, 95%) as a light yellow solid. 1 H NMR (400MHz, DMSO-d6) δ11.01(s,1H),8.68(s,1H),8.07(s,1H),7.80(d,J=8.6Hz,2H),7.55-7.45(m,5H) ,7.38-7.36(m,2H),6.74(s,1H),4.79(hept,J=6.8Hz,1H),4.55(d,J=12.3Hz,1H),4.07(d,J=13.0Hz,1H ),3.42(tt,J=11.8,3.3Hz,1H),3.24-3.18(m,1H),2.91(hept,J=6.7Hz,1H),2.70(t,J=12.0Hz,1H),2.0 7-1.99(m,2H),1.68-1.51(m,2H),1.44(d,J=6.8Hz,6H),1.03(d,J=7.0Hz,3H),1.01(d,J=7.0Hz,3H)ppm; 13C NMR (101MHz, DMSO-d6) δ174.55,163.26,160.65,152.60,150.48,147.46,142.28,138.14,137.56,135.87,130.21,129.89,129.50,129. C 35 H 38 N8O4(MW 634.74), LCMS(EI)m / e 635.3(M + +H); acid titration, sulfuric acid: free base = 0.50; elemental analysis for sulfur, calculated value 2.34%, observed value 2.29%.

[0413] Example 3. Alternative Synthesis of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound II)

[0414] Process 3

[0415]

[0416] Step 1. 1-Isopropyl-2,4-dioxo-3-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound 8).

[0417] A 5L 4-neck round bottom flask equipped with a mechanical stirrer, a thermocouple, a nitrogen inlet and a nitrogen outlet was charged with 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Compound 7, 202 g, 0.736 mol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)aniline (169 g, 0.773 mol) in N,N-dimethylformamide (DMF, 1.2 L) at room temperature. 2-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)-1,1,3,3-tetramethylisourea hexafluorophosphate (V) (HATU, 336 g, 0.884 mmol) was added to the mixture at room temperature. After cooling to an internal temperature below 15 ° C, triethylamine (NEt3, 97g, 0.957mol) was added to the mixture. The reaction mixture was then stirred for 4 hours at 15-25 ° C. Water (1.2L) was slowly added to precipitate the product. Solids were collected by filtration and washed with water (3×0.6L). In a vacuum oven, the filter cake was dried at 50 ° C under a gentle nitrogen purge to obtain 1-isopropyl-2,4-dioxo-3-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (compound 8, 363g, 104%) as a white solid. 1 H NMR(600MHz,DMSO-d6)δ10.99(s,1H),8.65(s,1H),7.68-7.63(m,4H),7.53-7.51(m,2H),7.48-7.45( m,1H),7.36(dd,J=8.2,1.2Hz,2H),4.78(hept,J=6.8Hz,1H),1.43(d,J=6.8Hz,6H),1.29(s,12H)ppm; 13 C NMR(150MHz,DMSO-d6)δ163.24,160.69,150.46,147.50,141.32,135.96,135.83, 129.47,129.09,129.03,124.09,119.19,105.10,83.98,50.89,25.14,21.18ppm; C 26 H 30 BN3O5(MW475.35), LCMS(EI)m / e 476.3(M + +H).

[0418] Step 2. tert-Butyl 4-(4-amino-5-(4-(1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 9)

[0419] A 22 L 5-neck round bottom flask equipped with a mechanical stirrer, a reflux condenser, a thermocouple, a heating mantle, a nitrogen inlet and a nitrogen outlet was charged with tert-butyl 4-(4-amino-5-bromopyrrolo[2,1-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 1, 557 g, 1.406 mol), 1-isopropyl-2,4-dioxo-3-phenyl-N-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound 8, 735 g, 1.546 mol) and tripotassium phosphate (K3PO4, 597 g, 2.811 mol) in 1,4-dioxane (6.0 L) and water (1.1 L) at room temperature. The mixture was degassed and refilled with a nitrogen atmosphere. Chloro(2-dicyclohexylphosphino-2',4',6'-triisopropyl-1,1'-biphenyl)[2-(2'-amino-1,1'-biphenyl)]palladium(II) (XPhos Pd G2, 77 g, 98 mmol) was added to the reaction mixture. The reaction mixture was degassed, refilled with a nitrogen atmosphere and heated to 80°C. After stirring at 80°C for 3 hours, water (6.0 L) was added to the reactant within one hour. The resulting solid was collected by filtration at 20°C and washed with water (2×3.0 L) and n-heptane (2×2.0 L). The filter cake was transferred back to a 22L round-bottom flask and slurried in ethyl acetate (EtOAc, 6.0 L) and methyl tert-butyl ether (MTBE, 2.2 L) at room temperature. The suspension was heated to 55°C and stirred for 2 hours. After the mixture was cooled to 20°C, the solid was collected by filtration and washed with MTBE (2×1.0 L). The filter cake was dried under vacuum on the filter funnel for 2 days to afford tert-butyl 4-(4-amino-5-(4-(1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 9, 827 g, 85%) as a light brown solid. 1H NMR(500MHz,DMSO-d6)δ10.97(s,1H),8.67(s,1H),7.90(s,1H),7.78(d,J=8.6Hz,2H),7 .54(t,J=7.5Hz,2H),7.48-7.46(m,1H),7.43(d,J=8.6Hz,2H),7.38-7.36(m,2H),6.58( s,1H),4.79(hept,J=6.7Hz,1H),4.08-4.03(m,2H),3.34-3.28(m,1H),2.89(s,2H),1.9 9(d,J=11.4Hz,2H),1.56(qd,J=12.7,4.1Hz,2H),1.44(d,J=6.8Hz,6H),1.42(s,9H)ppm; 13 C NMR (126MHz, DMSO-d6) δ163.25,160.57,156.20,154.33,150.49,147.78,147.40,135.56,135.89,134.56,131.20,130.24 ,129.49,129.12,129.03,120.42,117.99,109.88,109.35,105.16,79.08,50.91,43.90,32.71,30.54,28.59,21.11ppm; C 36 H 40 N8O5(MW 664.76), LCMS(EI)m / e 665.3(M + +H).

[0420] Step 3. N-(4-(4-amino-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide dihydrochloride (Compound 10)

[0421] A 22L 5-neck round bottom flask equipped with a mechanical stirrer, reflux condenser, thermocouple, heating mantle, nitrogen inlet and nitrogen outlet was charged with tert-butyl 4-(4-amino-5-(4-(1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamido)phenyl)pyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 9, 737 g, 1.053 mol) in dichloromethane (DCM, 4.5 L) at room temperature. 2-Propanol containing hydrochloric acid (5.8 N in IPA, 1.474 L, 8.549 mol, 8.12 equiv) was added to the suspension. The mixture was heated to 35-40°C. After 3 hours at 35-40°C, the reaction mixture was cooled to 15°C. Water (0.4L) was added, and the mixture was stirred for 1 hour at 15 °C. The mixture was diluted with DCM (9.0L). Solids were collected by filtration and washed with DCM (2 × 0.2L). On the filter funnel, the filter cake was dried under vacuum for 2 days to obtain N- (4- (4- amino -7- (piperidin -4- bases) pyrrolo [1,2-f] [1,2,4] triazine -5- bases) phenyl) -1- isopropyl -2,4- dioxo -3- phenyl -1,2,3,4- tetrahydropyrimidine -5- carboxamide dihydrochloride (630g, 94%) in a needle-shaped solid. 1 H NMR(500MHz,DMSO-d6)δ11.03(s,1H),9.31-9.21(m,3H),8.68(s,1H),8.29(s,1H) ),7.83(d,J=8.7Hz,2H),7.55-7.46(m,5H),7.38-7.37(m,2H),6.80(s,1H),4.83 (hept,J=6.8Hz,1H),3.50(tt,J=11.7,3.4Hz,1H),3.35(d,J=12.4Hz,2H),3.08( q,J=12.5Hz,2H),2.18-2.15(m,2H),1.99-1.96(m,2H),1.44(d,J=6.8Hz,6H)ppm; 13 C NMR (126MHz, DMSO-d6) δ163.26,160.70,150.47,150.38,147.52,138.68,138.59,138.06,135.86,130.21,129 .50,129.12,129.05,128.76,126.12,120.66,111.81,107.49,105.09,50.96,43.19,30.65,27.07,21.19ppm; C 31 H 32N8O3(MW 564.64), LCMS(EI)m / e 565.3(M + +H).

[0422] Step 4. N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (Compound II).

[0423] A 22 L 5-neck round bottom flask equipped with a mechanical stirrer, a thermocouple, a nitrogen inlet and a nitrogen outlet was charged with N-(4-(4-amino-7-(piperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide dihydrochloride (608 g, 0.954 mol) in dichloromethane (DCM, 17.6 L) at room temperature. Aqueous sodium hydroxide solution (NaOH, 1 N, 3.815 L, 3.815 mol) was added to the suspension. After stirring at room temperature for 1 hour, the mixture was cooled to 0-5°C and treated with isobutyryl chloride (107 g, 1.001 mol). The reaction mixture was stirred at room temperature for 24 hours. After the reaction was complete, the mixture was filtered through a celite pad. The organic phase is separated, washed with water (2×2.5L), and concentrated under reduced pressure. DCM (2.4L) and methyl tert-butyl ether (MTBE, 9.7L) are added to the residue. The mixture is heated to 50°C and stirred for 1 hour. After cooling to room temperature, the resulting solid is collected by filtration. The filter cake is dried on the filter under vacuum for 24 hours to obtain N- (4- (4- amino -7- (1- isobutyryl piperidine -4- bases) pyrrolo [1,2-f] [1,2,4] triazine -5- bases) phenyl) -1- isopropyl -2,4- dioxo -3- phenyl -1,2,3,4- tetrahydropyrimidine -5- carboxamide (compound II, 548g, 91%) as a light yellow solid. 1H NMR (500MHz, DMSO-d6) δ11.03(s,1H),8.68(s,1H),8.19(s,1H),7.82(d,J=8.6Hz,2H),7.55-7.46(m,5H),7.38-7.36(m ,2H),6.85(s,1H),4.79(hept,J=6.8Hz,1H),4.55(d,J=12.3Hz,1H),4.08(d,J=12.9Hz,1H),3.43(tt,J=11.8,3.5Hz,1 H),3.21(t,J=12.4Hz,1H),2.90(hept,J=6.7Hz,1H),2.70(t,J=12.2Hz,1H),2.02(dd,J=23.0,13.5Hz,2H),1.66(q,J= 11.8,11.3Hz,1H),1.53(q,J=12.2,11.7Hz,1H),1.44(d,J=6.8Hz,6H),1.03(d,J=7.0Hz,3H),1.01(d,J=7.0Hz,3H)ppm; 13 C NMR (126MHz, DMSO-d6) δ174.55,163.26,160.65,152.60,150.48,147.46,142.27,138.14,137.56,135.87,130.21,129.89,129.50,129. C 35 H 38 N8O4(MW 634.74), LCMS(EI)m / e 635.3(M + +H).

[0424] Example 4. Synthesis of tert-butyl 4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazine-7-yl)piperidine-1-carboxylate (Compound 1 of Scheme 1 and Scheme 2)

[0425] Process 4

[0426]

[0427] Step 1. tert-Butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Compound 13)

[0428] At room temperature, a 3L round-bottom flask equipped with a mechanical stirrer, a heating jacket, a thermocouple, a reflux condenser, a nitrogen inlet and a nitrogen outlet was charged with 1,4-dioxane (876 mL) containing 7-bromopyrrolo[1,2-f][1,2,4]triazine-4-amine (compound 11, 100 g, 469 mmol) and 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6-dihydropyridine-1(2H)-tert-butyl carboxylate (compound 12, 174 g, 563 mmol). Potassium carbonate (130 g, 939 mmol) and water (218 g) were sequentially added to the reaction flask. The reaction mixture was degassed by exposure to vacuum and refilled with a nitrogen atmosphere for three times. After adding tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4, 13.56 g, 11.7 mmol), the reaction mixture was degassed at room temperature and refilled with nitrogen for three times. The reaction mixture was then heated to 85-90°C and stirred at said temperature for 16 hours. After completion of the reaction, water (900 mL) was added over 30 minutes while the internal temperature was above 50°C. The mixture was cooled to room temperature. Solids gradually precipitated out. The solids were collected by filtration at 18°C ​​and washed with water (2×250 mL) and methyl tert-butyl ether (MTBE, 3×200 mL). The wet cake was returned to the reaction flask and stirred in MTBE (750 mL) at 50°C for 1 hour. The solids were collected by filtration at room temperature. The filter cake was dried in a vacuum oven at 50 °C under vacuum with a nitrogen purge for 72 hours to obtain tert-butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Compound 13, 123.7 g, 84%) as a brown solid. 1 H NMR(500MHz,DMSO-d6)δ7.89(s,1H),7.69(s,2H),7.00(s,1H),6.91(d,J=4.6Hz,1H),6.69 (d,J=4.5Hz,1H),4.06(s,2H),3.55(t,J=5.5Hz,2H),2.59-2.52(m,2H),1.43(s,9H)ppm; C 16 H 21 N5O2(MW 315.37), LCMS(EI)m / e 316.1(M + +H).

[0429] Step 2. tert-Butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 14)

[0430] At room temperature, a 2L flask was charged with acetic acid (1000 mL) containing tert-butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazine-7-yl)-5,6-dihydropyridine-1(2H)-carboxylate (Compound 13, 50.0 g, 159 mmol) and platinum (IV) oxide (10.0 g, 44 mmol). The flask was placed on a Parr Shaker under 50 psi hydrogen. After 16 hours, the reaction mixture was filtered through a diatomaceous earth pad (50 g) and washed with methanol (500 mL). The filtrate was concentrated under reduced pressure. Methyl tert-butyl ether (MTBE, 600 mL) was added to the residue at room temperature. A solution of potassium carbonate (about 50 g) in water (1200 mL) was added to the MTBE solution to adjust the pH to 6-7. The solid was collected by filtration and washed with water (2×300 mL) and n-heptane (2×300 mL). The filter cake was dried in a vacuum oven at 50° C. under vacuum with a nitrogen purge for 16 hours to afford tert-butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazine-7-yl)piperidine-1-carboxylate (Compound 14, 49.3 g, 98%) as a light brown solid. 1 H NMR (500MHz, DMSO-d6) δ7.82(s,1H),7.59(s,2H),6.81(d,J=4.4Hz,1H),6.44(d,J=4.3Hz,1H),4.05(d,J=11.3Hz,2H ), 3.25(tt,J=11.8,3.3Hz,1H),2.88(s,2H),1.95(d,J=11.9Hz,2H),1.51(qd,J=12.6,4.0Hz,2H),1.42(s,9H)ppm; C 16 H 23 N5O2(MW 317.39), LCMS(EI)m / e 318.1(M + +H).

[0431] Step 3. tert-Butyl 4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 1)

[0432] At room temperature, a 5-neck 22L round-bottom flask equipped with a mechanical stirrer, a thermocouple, a reflux condenser, a nitrogen inlet and a nitrogen outlet was charged with tetrahydrofuran (THF, 14.0L) containing tert-butyl 4-(4-aminopyrrolo[1,2-f][1,2,4]triazine-7-yl)piperidine-1-carboxylate (compound 14, 730g, 2.30mol). The mixture was cooled to 0-5°C. N-bromosuccinimide (NBS, 409g, 2.30mol) was added to the reaction mixture within 5 minutes while maintaining the internal temperature below 15°C. After stirring for 1 hour below 10°C, some solvent (9.0L) was removed under reduced pressure. A solution of sodium bicarbonate (140g, 1.67mol) in water (14.0L) was added to the residual solution within 5 minutes. Solid precipitation was precipitated. The solid was collected by filtration and washed with water (7.0L) and n-heptane (4L). The wet cake was dried on the filter under house vacuum for 48 hours to afford tert-butyl 4-(4-amino-5-bromopyrrolo[1,2-f][1,2,4]triazin-7-yl)piperidine-1-carboxylate (Compound 1, 886 g, 97%) as a brown solid. 1 H NMR (400MHz, DMSO-d6) δ7.86 (s, 1H), 6.66 (s, 1H), 4.04 (d, J = 11.0Hz, 2H), 3.30-3.23 (m, 1 H),2.86(br.s,2H),1.92(d,J=12.4Hz,2H),1.50(qd,J=12.8,4.1Hz,2H),1.41(s,9H)ppm; 13 C NMR (101MHz, DMSO-d6) δ155.68,154.29,148.35,135.37,111.31,110.68,87.29,79.10,43.97,32.63,30.37,28.58ppm; C 16 H 22 BrN5O2(MW 395.10), LCMS(EI)m / e 396.1(M + +H).

[0433] Example 5. Synthesis of 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Compound 7 in Schemes 2 and 3)

[0434] Step 1: Diethyl 2-((3-phenylureido)methylene)malonate

[0435]

[0436] To a mixture of diethyl (aminomethylene)malonate (6.0 g, 32 mmol) and phenyl isocyanate (3.8 mL, 35 mmol) in 1,2-dichloroethane (20 mL) was added N,N-diisopropylethylamine (7.2 mL, 42 mmol) at room temperature. The reaction mixture was then stirred overnight at 70 ° C, cooled to room temperature, Et2O (50 mL) was added, and stirred for another 30 minutes. The resulting solid was collected by filtration, washed with ether and dried to give the product as a white solid (4.88 g, 50%). LCMSC 15 H 19 N2O5(M+H) + Calculated value: m / z = 307.1. Found value: 307.2.

[0437] Step 2: Ethyl 2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate

[0438]

[0439] A mixture of diethyl 2-((3-phenylureido)methylene)malonate (4.88 g, 15.9 mmol) from the previous step and 2.5 M NaOEt in EtOH (13 mL, 32 mmol) in EtOH (20 mL) was stirred at room temperature for 1 hour. The resulting mixture was diluted with EtOAc, washed / acidified with 1 N citric acid, washed with water, brine, dried over Na2SO4 and concentrated to give the crude product as a white solid, which was used directly in the next step (4.1 g, 99%). LCMS C 13 H 13 N2O4(M+H) + Calculated value: m / z = 261.1. Found value: 261.1.

[0440] Step 3: 1-Isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester

[0441]

[0442] A mixture of ethyl 2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1.50 g, 5.76 mmol) from the previous step, isopropyl iodide (1.2 mL, 12 mmol) and Cs2CO3 (5.6 g, 17 mmol) in DMF (20 mL) was stirred at 50°C for 5 hours. The reaction mixture was then cooled to room temperature, diluted with EtOAc, washed with water, brine, dried over Na2SO4 and concentrated to give the crude product, which was used directly in the next step. LCMS C 16 H 19N2O4(M+H) + Calculated value: m / z = 303.1. Found value: 303.1.

[0443] Step 4: 1-Isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

[0444]

[0445] A mixture of ethyl 1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxylate (1.70 g, 5.62 mmol) from the previous step in 4.0 M HCl / 1,4-dioxane (9.8 mL, 39 mmol) and water (2.1 mL) was stirred at 60° C. for 4 hours, cooled to room temperature, and water was added. The resulting solid was then collected by filtration (washed with water) to give the product as a white solid (1.1 g, 71%). LCMS C 14 H 15 N2O4(M+H) + Calculated value: m / z = 275.1. Found value: 275.1.

[0446] Example 6. Synthesis of 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid (Compound 6 in Scheme 1)

[0447] Step 1: Diethyl 2-((3-pyridin-2-ylureido)methylene)malonate

[0448]

[0449] To a mixture of diethyl 2-(aminomethylene)malonate (3.0 g, 16.0 mmol) and 2-isocyanatopyridine (2.02 g, 16.8 mmol) in 1,2-dichloroethane (9.0 mL) was added N,N-diisopropylethylamine (3.6 mL, 20.8 mmol) at room temperature. The reaction mixture was then stirred at 70 °C overnight, cooled to room temperature, and purified directly via column chromatography (0% to 15% MeOH / CH2Cl2) to give the product (3.18 g, 65%). LCMS C 14 H 18 N3O5(M+H) + Calculated value: m / z = 308.1. Found value: 308.1.

[0450] Step 2: 1-Isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid

[0451]

[0452] A mixture of diethyl 2-((3-(pyridin-2-yl)ureido)methylene)malonate (3.18 g, 10.4 mmol) and 2.5 M NaOEt / EtOH (6.2 mL, 15.5 mmol) in EtOH (25 mL) was stirred at room temperature for 3 hours. The resulting mixture was diluted with EtOAc and washed / acidified with 1N citric acid solution (30 mL). The organic layer was separated and the aqueous layer was further extracted with 3:1 CHCl3 / isopropanol (30 mL×3). The combined organic layers were dried over Na2SO4 and concentrated to give a crude product of ethyl 2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate, which was used directly in the next step. LCMS C 12 H 12 N3O4(M+H) + Calculated value: m / z = 262.1. Found value: 262.2.

[0453] A mixture of crude ethyl 2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate from the previous step, 2-iodopropane (2.06 mL, 20.7 mmol) and Cs2CO3 (10.1 g, 31.0 mmol) in DMF (35 mL) was stirred at 70°C for 3 hours. The reaction mixture was then cooled to room temperature, diluted with 3:1 CHCl3 / isopropanol (75 mL), washed with water, brine, dried over Na2SO4 and concentrated to give the crude product ethyl 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylate, which was used directly in the next step. LCMS C 15 H 18 N3O4(M+H) + Calculated value: m / z = 304.1. Found value: 304.1.

[0454] A mixture of crude 1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester from the previous step in 4M HCl / 1,4-dioxane (20 mL, 82 mmol) and water (5.0 mL) was stirred at 80°C for 5 hours, cooled to room temperature and concentrated. The resulting material was then purified via column chromatography (0% to 15% MeOH / CH2Cl2) to give the product as a slightly yellow solid (1.50 g, 47% for three steps). LCMS C 13 H 14 N3O4(M+H) + Calculated value: m / z = 276.1. Found value: 276.1.

[0455] Example 7. Solid State Characterization of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate (Compound I Maleate, Form I)

[0456] X-ray powder diffraction (XRPD) of Compound I maleate salt

[0457] X-ray powder diffraction (XRPD) was obtained by Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was: (1) X-ray irradiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min. The XRPD pattern is shown in Figure 1 The XRPD data are provided in Table 1.

[0458] Table 1. XRPD data: Maleate salt of compound of formula I (Form I)

[0459] 2θ(°) high H% 4.3 5452 89.8 5.8 63 1.0 8.4 6068 100 12.6 177 2.9 13.2 331 5.5 15.8 120 2.0 17.1 132 2.2 18.5 230 3.8 20.3 136 2.2 20.9 89 1.5 23.1 114 1.9 24.0 118 1.9 25.2 137 2.3 28.4 45 0.7 29.7 44 0.7 31.5 59 1.0 35.7 102 1.7 42.6 40 0.7

[0460] Differential Scanning Calorimetry (DSC) of Compound 1 Maleate Salt (Form I)

[0461] DSC was obtained by a TA Instruments differential scanning calorimeter model Q200 with an autosampler. The DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min. The DSC thermogram is shown in Figure 2 The DSC thermogram showed a major endothermic event with an onset temperature of 202.9°C and a peak temperature of 211.0°C, which was considered to be the melting and decomposition temperature of the compound.

[0462] Thermogravimetric analysis (TGA) of Compound 1 maleate salt (Form I)

[0463] TGA was obtained by a TA Instrument Thermogravimetric Analyzer Model Q500. General experimental conditions for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish. TGA thermograms are shown in Figure 3A weight loss of about 0.7% was observed up to 150°C and is believed to be related to the loss of moisture and residual solvent. The compound begins to decompose significantly above 200°C.

[0464] Solubility of Compound I Maleate Salt (Form I)

[0465] The solubility of Compound I maleate salt was measured at 25±1°C and at 50±1°C. The general procedure for testing the solubility at 25±1°C was as follows: 1) 3 mL of each solvent listed in Table 1A was added to individual vials; 2) Compound I maleate salt was added at 25°C to form a turbid solution; 3) an additional 15-20 mg of Compound I maleate salt was added; 4) the mixture was stirred at 25±1°C for 48 hours; 5) the supernatant was filtered using a syringe filter; and 6) the saturated solution was diluted with MeOH and analyzed by HPLC. The general procedure for testing solubility at 50±1°C is as follows: 1) 3 mL of each solvent listed in Table 1A is added to individual vials; 2) Compound I maleate is added at 50°C to form a turbid solution; 3) an additional 20-25 mg of Compound I maleate is added; 4) the mixture is stirred at 50±1°C for 24 hours; 5) the supernatant is filtered at 50±1°C using a heated syringe filter; and 6) the saturated solution is diluted with MeOH and analyzed by HPLC. The results are summarized in Table 1A.

[0466] Table 1A.

[0467]

[0468]

[0469] Other crystalline salts

[0470] Other crystalline salts of the compound of formula I have been discovered and prepared, such as the hydrochloride, monosulfate, hemisulfate, methanesulfonate and benzenesulfonate salts.

[0471] Example 8: Preparation of a salt of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide (salt of compound II)

[0472] Salts of Compound II were prepared according to the procedure in Table 2 below. The salts were analyzed by XRPD, DSC and TGA (see Examples 9 to 15).

[0473] Table 2.

[0474]

[0475]

[0476]

[0477] Example 9. Solid-state characterization of Compound II phosphate

[0478] X-ray powder diffraction (XRPD) study of compound II phosphate

[0479] The phosphate salt of Compound II was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was: (1) X-ray radiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0480] The XRPD pattern of Compound II phosphate is shown in Figure 4 The XRPD data are provided in Table 3.

[0481] Table 3.

[0482] 2θ(°) high H% 3.8 87 21.8 5.3 194 48.6 6.5 69 17.3 9.1 203 50.9 11.2 79 19.8 12.3 135 33.8 12.9 102 25.6 14.9 399 100 15.8 394 98.7 17.5 194 48.6 19.3 290 72.7 21.1 98 24.6 21.4 111 27.8 22.4 163 40.9 23.9 68 17 24.4 144 36.1 25.6 86 21.6 28.3 39 9.8 32.7 33 8.3 33.9 68 17 40.3 42 10.5 43.4 50 12.5

[0483] Differential Scanning Calorimetry (DSC) Study of Compound II Phosphate

[0484] The phosphate salt of Compound II was characterized by DSC.DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler.DSC instrument conditions were as follows: 30-350°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0485] The DSC thermogram of Compound II phosphate is shown in Figure 5 The DSC thermogram showed a major endothermic event with an onset temperature of 252.6°C and a peak temperature of 257.2°C, which was believed to be melting / decomposition of the compound.

[0486] Thermogravimetric analysis (TGA) study of compound II phosphate

[0487] The phosphate salt of Compound II was characterized by TGA. The TGA was obtained on a TA Instrument Thermogravimetric Analyzer Model Q500. The general experimental conditions used for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0488] The TGA thermogram of Compound II phosphate is shown in Figure 6 A weight loss of about 1.8% was observed up to 200°C and is believed to be related to loss of moisture or residual solvent. A significant weight loss was observed above 230°C and is believed to be related to decomposition of the compound.

[0489] Example 10. Solid-state characterization of compound II maleate salt

[0490] X-ray powder diffraction (XRPD) study of compound II maleate

[0491] The maleate salt of Compound II was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was: (1) X-ray radiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0492] The XRPD pattern of the maleate salt of Compound II is shown in Figure 7 The XRPD data are provided in Table 4.

[0493] Table 4.

[0494]

[0495]

[0496] Differential Scanning Calorimetry (DSC) Study on the Maleate Salt of Compound II

[0497] The maleate salt of Compound II was characterized by DSC.DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler.DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0498] The DSC thermogram of the maleate salt of Compound II is shown in Figure 8The DSC thermogram shows two major endothermic events, with the first event having an onset temperature of 183.4°C and a peak temperature of 194.8°C, followed by a second event having an onset temperature of 233.4°C and a peak temperature of 239.7°C.

[0499] Thermogravimetric analysis (TGA) study of the maleate salt of compound II

[0500] The maleate salt of Compound II was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer Model Q500. The general experimental conditions used for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0501] The TGA thermogram of the maleate salt of Compound II is shown in Fig. 9 A weight loss of about 1.8% was observed up to 125°C and is believed to be related to loss of moisture or residual solvent. A significant weight loss was observed above 175°C and is believed to be related to decomposition of the compound.

[0502] Example 11. Solid-state characterization of compound II hemisulfate salt

[0503] X-ray powder diffraction (XRPD) study of compound II hemisulfate

[0504] The hemisulfate salt of Compound II was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was: (1) X-ray radiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0505] The XRPD pattern of Compound II hemisulfate salt is shown in Fig.10 The XRPD data are provided in Table 5.

[0506] Table 5.

[0507] 2θ(°) high H% 5.3 348 100 8.5 335 96.3 10.4 78 22.4 13.0 51 14.7 13.4 73 21 15.3 128 36.8 16.4 50 14.4 18.6 65 18.7 19.0 48 13.8 20.1 90 25.9 21.2 41 11.8 21.9 67 19.3 22.9 50 14.4 23.4 51 14.7 24.9 89 25.6 26.7 41 11.8

[0508] Differential Scanning Calorimetry (DSC) Study on Hemisulfate of Compound II

[0509] The hemisulfate salt of Compound II was characterized by DSC.DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler.DSC instrument conditions were as follows: 30-350°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0510] The DSC thermogram of compound II hemisulfate is shown in Fig.11 The DSC thermogram showed a major endothermic event with an onset temperature of 283.8°C and a peak temperature of 289.4°C, which was believed to be the melting / decomposition of the compound.

[0511] Thermogravimetric analysis (TGA) study of compound II hemisulfate

[0512] The hemisulfate salt of Compound II was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer Model Q500. The general experimental conditions used for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0513] The TGA thermogram of compound II hemisulfate is shown in Fig.12 A weight loss of about 1.5% was observed up to 100°C and is believed to be related to the loss of moisture or residual solvent. Significant weight loss was observed above 200°C in several steps and is believed to be related to the decomposition of the compounds.

[0514] Example 12. Solid-state characterization of compound II hydrochloride

[0515] X-ray powder diffraction (XRPD) study of compound II hydrochloride

[0516] The hydrochloride salt of Compound II was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was: (1) X-ray radiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0517] The XRPD pattern of Compound II hydrochloride is shown in Fig.13 The XRPD data are provided in Table 6.

[0518] Table 6.

[0519] 2θ(°) high H% 4.4 56 11.2 6.5 502 100 9.7 141 28.1 10.3 99 19.7 13.1 37 7.4 13.9 78 15.5 14.9 96 19.1 16.5 84 16.7 17.0 40 8 18.9 83 16.5 19.7 73 14.5 20.9 54 10.8 21.5 169 33.7 21.8 114 22.7 23.9 130 25.9 25.1 37 7.4 25.7 38 7.6 27.4 50 10 29.1 44 8.8

[0520] Differential Scanning Calorimetry (DSC) Study of Compound II Hydrochloride

[0521] The hydrochloride salt of Compound II was characterized by DSC.DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler.DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0522] The DSC thermogram of Compound II hydrochloride is shown in Fig.14 The DSC thermogram showed a major endothermic event with an onset temperature of 183.5°C and a peak temperature of 190.0°C, which was believed to be the melting / decomposition of the compound.

[0523] Thermogravimetric analysis (TGA) study of compound II hydrochloride

[0524] The hydrochloride salt of Compound II was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer Model Q500. The general experimental conditions used for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0525] The TGA thermogram of Compound II hydrochloride is shown in Fig.15 A weight loss of about 5.9% was observed up to 200°C and is believed to be related to loss of moisture or residual solvent. A significant weight loss was observed above 200°C and is believed to be related to decomposition of the compound.

[0526] Example 13. Solid-state characterization of compound II salicylate

[0527] X-ray powder diffraction (XRPD) study of compound II salicylate

[0528] The salicylate salt of Compound II was characterized by XRPD. XRPD was obtained by a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was: (1) X-ray radiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0529] The XRPD pattern of Compound II salicylate is shown in Fig.16 The XRPD data are provided in Table 7.

[0530] Table 7.

[0531]

[0532]

[0533] Differential Scanning Calorimetry (DSC) Study of Compound II Salicylate

[0534] The salicylate salt of Compound II was characterized by DSC.DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler.DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0535] The DSC thermogram of compound II salicylate is shown in Fig.17 The DSC thermogram showed 3 major endothermic events: the first with an onset temperature of 176.0°C and a peak temperature of 181.7°C, the second with an onset temperature of 209.9°C and a peak temperature of 224.9°C, and the third with an onset temperature of 254.7°C and a peak temperature of 264.5°C.

[0536] Thermogravimetric analysis (TGA) study of compound II salicylate

[0537] The salicylate salt of Compound II was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer Model Q500. The general experimental conditions used for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0538] The TGA thermogram of compound II salicylate is shown in Fig.18 A weight loss of about 8.1% was observed up to 250°C in the first step. A significant weight loss was observed above 300°C and is believed to be associated with the decomposition of the compound.

[0539] Example 14. Solid-state characterization of compound II mesylate

[0540] X-ray powder diffraction (XRPD) study of compound II methanesulfonate

[0541] The mesylate salt of Compound II was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was: (1) X-ray radiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0542] The XRPD pattern of the mesylate salt of Compound II is shown in Fig.19 and XRPD data are provided in Table 8.

[0543] Table 8.

[0544] 2θ(°) high H% 5.0 106 23.7 8.2 447 100 13.2 76 17 16.9 141 31.5

[0545] Differential Scanning Calorimetry (DSC) Study of Compound II Methanesulfonate

[0546] The mesylate salt of Compound II was characterized by DSC.DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler.DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and cover; and nitrogen flow rate 50 mL / min.

[0547] The DSC thermogram of the mesylate salt of Compound II is shown in Fig. 20 The DSC thermogram shows a major endothermic event with an onset temperature of 166.3°C and a peak temperature of 174.8°C, which is believed to be the melting / decomposition of the compound.

[0548] Thermogravimetric analysis (TGA) study of compound II methanesulfonate

[0549] The mesylate salt of Compound II was characterized by TGA. The TGA was obtained on a TA Instrument Thermogravimetric Analyzer Model Q500. The general experimental conditions used for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0550] The TGA thermogram of the mesylate salt of Compound II is shown in Fig.21 A weight loss of about 2.3% was observed up to 100°C and is believed to be related to loss of moisture or residual solvent. A significant weight loss was observed above 200°C and is believed to be related to decomposition of the compound.

[0551] Example 15. Solid-state characterization of compound II ethanesulfonate

[0552] X-ray powder diffraction (XRPD) study of compound II ethanesulfonate

[0553] The ethanesulfonate salt of Compound II was characterized by XRPD. XRPD was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure for XRPD was: (1) X-ray radiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0554] The XRPD pattern of Compound II ethanesulfonate is shown in Fig. 22 The XRPD data are provided in Table 9.

[0555] Table 9.

[0556]

[0557]

[0558] Differential Scanning Calorimetry (DSC) Study on Ethysulfonate of Compound II

[0559] The ethanesulfonate salt of Compound II was characterized by DSC.DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler.DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0560] The DSC thermogram of the ethanesulfonate of Compound II is shown in Fig.23 The DSC thermogram showed a major endothermic event with an onset temperature of 180.4°C and a peak temperature of 187.7°C, which was believed to be the melting / decomposition of the compound.

[0561] Thermogravimetric analysis (TGA) study of compound II ethanesulfonate

[0562] The ethanesulfonate salt of Compound II was characterized by TGA. The TGA was obtained from a TA Instrument Thermogravimetric Analyzer Model Q500. The general experimental conditions for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0563] The TGA thermogram of compound II ethanesulfonate is shown in Fig.24 A weight loss of about 1.6% was observed up to 100°C and is believed to be related to loss of moisture or residual solvent. A significant weight loss was observed above 200°C and is believed to be related to decomposition of the compound.

[0564] Example 16. Preparation of Other Crystalline Forms of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide Maleate (Compound I Maleate, Form II-V)

[0565] The experimental procedure used to form Compound I maleate salt Forms II, III, IV and V is summarized in Table 10.

[0566] Table 10. Crystallization procedure for forming the solid form of the maleate salt of Compound 1

[0567]

[0568] Example 17. Solid State Characterization of Compound I Maleate Salt Form II

[0569] X-ray Powder Diffraction (XRPD) of Compound I Maleate Salt Form II

[0570] X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure used for XRPD was: (1) X-ray irradiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0571] The XRPD pattern of Compound I maleate salt Form II is shown in Fig.25 and XRPD data are provided in Table 11.

[0572] Table 11.

[0573] 2θ(°) high H% 3.8 500 100 7.8 268 53.6 12.3 65 13 19.7 70 14 23.5 128 25.6 26.0 90 18 26.7 52 10.4

[0574] Example 18. Solid State Characterization of Compound I Maleate Salt Form III

[0575] X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure used for XRPD was: (1) X-ray irradiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0576] The XRPD pattern of Compound I maleate salt Form III is shown at Fig.26 and XRPD data are provided in Table 12.

[0577] Table 12.

[0578]

[0579]

[0580] Differential Scanning Calorimetry (DSC) Study of Compound I Maleate Salt Form III

[0581] Compound I Maleate Salt Form III was characterized by DSC. DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with an autosampler. DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0582] The DSC thermogram of Compound I maleate salt form III is shown in Fig. 27 The DSC thermogram showed two endothermic events: the first with an onset temperature of 143.9°C and a peak temperature of 165.4°C, and the second with an onset temperature of 186.3°C and a peak temperature of 195.4°C.

[0583] Thermogravimetric analysis (TGA) studies of Compound I maleate salt Form III

[0584] Compound I maleate salt Form III was characterized by TGA. TGA was obtained from a TA Instrument thermogravimetric analyzer model Q500. General experimental conditions for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0585] The TGA thermogram of Compound I maleate salt form III is shown in Fig.28 middle.

[0586] Example 19. Solid State Characterization of Compound I Maleate Salt Form IV

[0587] X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure used for XRPD was: (1) X-ray irradiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0588] The XRPD pattern of Compound 1 maleate salt Form IV is shown at Fig.29 and XRPD data are provided in Table 13.

[0589] Table 13.

[0590]

[0591]

[0592] Differential Scanning Calorimetry (DSC) Study of Compound I Maleate Salt Form IV

[0593] Compound I Maleate Salt Form IV was characterized by DSC. DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with autosampler. DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0594] The DSC thermogram of Compound I maleate salt form IV is shown in Fig.30 The DSC thermogram showed two endothermic events: the first with an onset temperature of 145.7°C and a peak temperature of 152.1°C, and the second with an onset temperature of 188.3°C and a peak temperature of 202.6°C.

[0595] Thermogravimetric analysis (TGA) studies of Compound I maleate salt Form IV

[0596] Compound I maleate salt Form IV was characterized by TGA. TGA was obtained from a TA Instrument thermogravimetric analyzer model Q500. General experimental conditions for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample dish.

[0597] The TGA thermogram of Compound I maleate salt form IV is shown in Fig.31 middle.

[0598] Example 20. Solid State Characterization of Compound I Maleate Salt Form V

[0599] X-ray powder diffraction (XRPD) was obtained from a Rigaku MiniFlex X-ray powder diffractometer (XRPD). The general experimental procedure used for XRPD was: (1) X-ray irradiation of copper, Using K β filter; (2) X-ray power 30KV, 15mA; and (3) sample powder is dispersed on a zero background sample container. The general measurement conditions for XRPD are: starting angle 3°; ending angle 45°; sampling 0.02°; and scanning speed 2° / min.

[0600] The XRPD pattern of Compound 1 maleate salt Form V is shown at Fig.32 and XRPD data are provided in Table 14.

[0601] Table 14.

[0602] 2θ(°) high H% 4.1 423 95.3 8.3 444 100 8.8 140 31.5 10.7 43 9.7 12.5 35 7.9 13.0 34 7.7 15.6 44 9.9 18.0 130 29.3 20.5 41 9.2 23.1 53 11.9 23.5 122 27.5 24.1 38 8.6 27.3 150 33.8 28.4 42 9.5 29.4 36 8.1 31.4 43 9.7 35.5 49 11

[0603] Differential Scanning Calorimetry (DSC) Study of Compound I Maleate Salt Form V

[0604] Compound I Maleate Salt Form V was characterized by DSC. DSC was obtained from a TA Instruments Differential Scanning Calorimeter Model Q200 with autosampler. DSC instrument conditions were as follows: 30-300°C, 10°C / min; T0 aluminum sample pan and lid; and nitrogen flow rate 50 mL / min.

[0605] The DSC thermogram of Compound I maleate salt form V is shown in Fig.33 The DSC thermogram shows an endothermic event with an onset temperature of 189.1 °C and a peak temperature of 200.1 °C.

[0606] Thermogravimetric analysis (TGA) studies of Compound I maleate salt Form V

[0607] Compound I Maleate Salt Form V was characterized by TGA. TGA was obtained from a TA Instrument Thermogravimetric Analyzer Model Q500. General experimental conditions for TGA were: 20°C / min from 20°C to 600°C; nitrogen purge, gas flow rate 40 mL / min, then purge flow rate to equilibrium; sample purge flow rate 60 mL / min; platinum sample pan.

[0608] The TGA thermogram of Compound I maleate salt Form V is shown in Fig.34 middle.

[0609] Example A

[0610] Axl autophosphorylation assay

[0611] Axl autophosphorylation was performed by incubating recombinant Axl protein (Life Technologies, PV4275) for 1 hour at room temperature in a buffer containing 50 mM Tris pH 7.5, 0.2 mg / ml Axl, 5 mM ATP, 20 mM MgCl2 and 2 mM DTT.

[0612] TAM enzyme assay

[0613] Kinase assay buffer contains 50mM HEPES pH 7.5, 10mM MgCl2, 1mM EGTA, 0.01% NP-40 and 2mM DTT. 0.1ul of test compound dissolved in DMSO is transferred from the compound plate to a white 384-well assay plate (Greiner LUMITRAC plate). The final concentration of DMSO is 1.25%. An enzyme solution of 5.1nM phosphorylated-Axl or 0.0625nM c-Mer (Carna Biosciences, 08-108) or 0.366nM Tyro3 (LifeTechnologies, PR7480A) is prepared in assay buffer. A 1mM stock solution of the peptide substrate biotin-EQEDEPEGDYFEWLE-amide SEQ ID NO: 1 (Quality Controlled Biochemicals, MA) dissolved in DMSO is diluted to 1uM in an assay buffer containing 2000uM ATP. 4ul enzyme solution (or the assay buffer for enzyme blank) is added to the appropriate wells in each flat plate, then 4ul / well substrate solution is added to initiate the reaction. The flat plate is kept in dark and incubated for 60 minutes at room temperature. The reaction is terminated by adding 4ul detection solution containing 50mM Tris-HCl pH 7.8, 150mM NaCl, 0.05% BSA, 45mM EDTA, 180nMSA-APC (Perkin Elmer, CR130-100) and 3nM Eu-W1024 anti-phosphotyrosine PY20 (Perkin Elmer, AD0067). At room temperature the flat plate is incubated for 1 hour, and HTRF (homogeneous time-resolved fluorescence) signal is measured on PHERAstar FS flat plate reader (BMG labtech). Calculate the inhibition percentage of each concentration and utilize GraphPad Prism software to produce IC50 value by curve fitting.

[0614] The compounds of Formula I and Formula II were found to be inhibitors of one or more of AXL, MER and TYRO3. The IC values ​​of the trifluoroacetate salts of the compounds of Formula I and Formula II are: 50 The data are disclosed in U.S. Application No. 15 / 469,975 and are provided in Table 15 below. Indicates IC 50 ≤5nM, Indicates IC 50 >5nM but ≤10nM, and Indicates IC 50 >10nM but ≤100nM.

[0615] Table 15

[0616]

[0617] Example B. Generation of BAF3-AXL, BAF3-MER and BAF3-TYRO3 cells and cell proliferation assays

[0618] The cytoplasmic domain of AXL, MER or TYRO3 fused with the dimerization sequence and HA tag was cloned into the pMSCV vector with a puromycin resistance marker to produce three constructs (pMSCV-AXL, pMSCV-MER and pMSCV-TYRO3). BAF3 cells were transfected one by one by electroporation with the three constructs. Single clones that were unrelated to IL3 and had puromycin resistance were selected and characterized. Cells stably expressing AXL, MER or TYRO3 were selected and named as BAF3-AXL cells, BAF3-MER cells and BAF3-TYRO3 cells.

[0619] BAF3, BAF3-AXL, BAF3-MER or BAF3-TYRO3 cell lines were maintained in RPMI1640 (Gibco / Life Technologies, Carlsbad, CA) containing 10% FBS. To measure the effect of test compounds on cell viability, 1000 cells / well were seeded into 384-well tissue culture plates in growth medium containing serial dilutions of compounds or DMSO alone, maintained at 37°C with 5% CO2 for 48 hours, and cell viability was measured by ATP determination (CellTiter-Glo Assay, Promega) according to the manufacturer's procedure. Data were converted to inhibition percentages relative to DMSO controls, and GraphPad Prism software was used to fit IC 50 curve.

[0620] Example C. BaF3-AXL ELISA and BaF3-MER ELISA

[0621] BaF3-AXL or BaF3-MER cells were maintained in RPMI medium containing 10% FBS and puromycin (1 μg / ml, Gibco / Life Technologies, Carlsbad, CA). To measure the effects of test compounds on phospho-AXL or phospho-MER, cells were plated (5×10 4 Cells / well) were placed in V-bottom polypropylene plates (Greiner bio-one) and incubated at 37°C with 5% CO2 for 1 hour. Cells were collected by centrifugation and dissolved in 110 μl of ice-cold lysis buffer (Cell Signaling) containing protease and phosphatase inhibitors (Halts PI, ThermoFisher) and maintained on ice for 30 minutes. Cell lysates were stored at -80°C for use in ELISA. ELISA plates were prepared by incubating Costar plates with anti-HA antibodies (1 μg / ml) for 1 hour at room temperature. The plates were washed and blocked with PBS containing 3% BSA. Cell lysates were loaded onto ELISA plates and incubated overnight at 4°C. The plates were washed and incubated in DELFIA assay buffer (Perkin Elmer) for 1 hour with LANCE Eu-W1024 anti-phosphotyrosine antibody (PY-20) (Perkin Elmer) and read on Pherastar (BMG Labtech). Data were converted to percent inhibition relative to DMSO control, and IC values ​​were calculated by fitting the percent inhibition curves to the logarithm of inhibitor concentration using GraphPad Prism. 50 Determination.

[0622] Example D. H1299 Phosphorylation-AXL ELISA

[0623] H1299 cells (ATCC), a human non-small cell lung cancer cell line with Axl expression, were maintained in RPMI (Gibco / Life Technologies, Carlsbad, CA) containing 10% FBS. To measure the effect of the test compounds on phosphorylated-AXL, cells were seeded (30,000 cells / well) in 96-well tissue culture plates (Costar) and incubated overnight at 37°C with 5% CO2. Compounds were added at appropriate concentrations and incubated at 37°C with 5% CO2 for 1 hour. rhGas6 (R&D Systems, 6 μg / ml) was added to each well. The plates were incubated at 37°C with 5% CO2 for 15 minutes. Cells were collected and dissolved in 110 μL of ice-cold lysis buffer (Cell Signaling) containing protease and phosphatase inhibitors (Halts PI, Thermo Fisher). Lysates were incubated on ice for 1 hour and stored at -80°C for use in ELISA. ELISA plates were prepared by incubating Costar plates with anti-HA antibody (1 μg / ml) for 1 hour at room temperature. The plates were washed and blocked with PBS containing 3% BSA. Cell lysates were loaded onto ELISA plates and incubated overnight at 4°C. The plates were washed and incubated with LANCE Eu-W1024 anti-phosphotyrosine antibody (PY-20) (Perkin Elmer) in DELFIA assay buffer (Perkin Elmer) for 1 hour and read on Pherastar (BMG Labtech). The data were converted to percent inhibition relative to the DMSO control and IC was calculated by fitting the percent inhibition curve relative to the logarithm of the inhibitor concentration using GraphPad Prism. 50 Determination.

[0624] Example E. Whole Blood H1299 Phosphorylation-AXL ELISA

[0625] H1299 cells (ATCC) were maintained in RPMI medium (Gibco / LifeTechnologies, Carlsbad, CA) containing 10% FBS. To measure the effect of the test compounds on phosphorylated-AXL in whole blood, cells were seeded (30,000 cells / well) in 96-well tissue culture plates (Costar) and incubated overnight at 37°C with 5% CO2. Blood obtained from normal donors was mixed with the test compounds for 1 hour. The culture medium was removed from the H1299 cells, and blood containing the compound was added to each well. After incubation at 37°C with 5% CO2 for 1 hour, rh-Gas6 (4 μg / ml, R&D Systems) was added to each well. The plate was incubated for 15 minutes at 37°C with 5% CO2. The cells were washed with PBS and dissolved in 110 uL of ice-cold lysis buffer (Cell Signaling) containing protease and phosphatase inhibitors (Halts PI, Thermo Fisher) and maintained on ice for 1 hour. The plates were stored at -80°C for use in ELISA. ELISA plates were prepared by incubating Costar plates with anti-HA antibody (1 ug / ml) for 1 hour at room temperature. The plates were washed and blocked with PBS containing 3% BSA. The cell lysates were loaded onto ELISA plates and incubated overnight at 4°C. The plates were washed and incubated with LANCE Eu-W1024 anti-phosphotyrosine antibody (PY-20) (Perkin Elmer) in DELFIA assay buffer (Perkin Elmer) for 1 hour and read on Pherastar (BMG Labtech). The data were converted to percent inhibition relative to the DMSO control and IC was calculated by fitting the percent inhibition curve relative to the logarithm of the inhibitor concentration using GraphPad Prism. 50 Determination.

[0626] Example F. G361 phosphorylation-Akt Cell Insight ELISA

[0627] G361 cells (ATCC), a human melanoma cell line expressing Mer, were maintained in RPMI medium (Gibco / Life Technologies, Carlsbad, CA) containing 10% FBS. To measure the effects of test compounds on the MER signaling pathway, cells were plated at 2×10 4Cells / well were seeded in 96-well CellBind plates (Corning) with a volume of 100 μL and incubated overnight at 37°C with 5% CO2. 20 μL of test compounds were added to the cells at appropriate concentrations and incubated for 1 hour. rhGas6 (4 μg / ml, R&D Systems) was added to each well and incubated for 20 minutes. Cells were fixed for 30 minutes at room temperature by adding 50 uL of PBS (Corning) containing 4% polyformaldehyde (Electron Microscopy Sciences). The plates were washed and incubated for 10 minutes at room temperature with 50 uL of PBS containing 0.2% triton X-100 (Sigma). The plates were washed and incubated for 30 minutes with 100 uL of blocking buffer (PBS containing 0.1% BSA). The plates were washed and incubated overnight at 4°C with phospho-AKT (Ser473) (D9E) rabbit mAb (Cell Signaling) diluted in 0.1% BSA (1:300 dilution). The plates were washed and incubated at room temperature with 50 uL of Alexaflour 488F (ab') containing goat anti-rabbit IgG (H+L) 2 Fragments (Molecular Probes, 1:1000 dilution) and Hoechst 33342 (Thermo Fisher, 1:2000 dilution) in PBS were incubated for 2 hours. Plates were washed with PBS and read on a Cell Insight CX5 (Thermo Fisher).

[0628] Based on the previous description, various modifications to the present invention other than those described herein should also be apparent to those skilled in the art. Such modifications are also intended to fall within the scope of the appended claims. Each reference cited in this application, including all patents, patent applications and publications, is incorporated herein by reference in its entirety.

[0629] This application also involves the following technical solutions:

[0630] Item 1. A salt, which is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate.

[0631] Item 2. A salt as described in Item 1, wherein the salt is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide and maleic acid.

[0632] Item 3. The salt according to Item 1, which is a crystalline salt.

[0633] Item 4. The salt according to Item 1, which is a substantially isolated salt.

[0634] Item 5. The salt of Item 1, characterized by a DSC thermogram having an endothermic peak at about 211°C.

[0635] Item 6. A salt as described in Item 1, wherein the salt has substantially Figure 2 DSC thermogram shown.

[0636] Item 7. A salt as described in Item 1, wherein the salt has substantially Figure 3 TGA thermogram shown.

[0637] Item 8. The salt of Item 1, which has at least one XRPD peak in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0638] Item 9. The salt of Item 1, which has at least two XRPD peaks in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0639] Item 10. The salt of Item 1, which has at least three XRPD peaks in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0640] Item 11. The salt of Item 1, which has at least four XRPD peaks in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0641] Item 12. The salt of Item 1, comprising the following XRPD peaks in terms of 2θ: about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

[0642] Item 13. A salt as described in Item 1, wherein the salt has substantially Figure 1 XRPD distribution shown.

[0643] Item 14. A salt, which is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hemisulfate.

[0644] Item 15. The salt of Item 14, wherein the salt is a 1:0.5 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide and sulfuric acid.

[0645] Item 16. The salt according to Item 14, which is a crystalline salt.

[0646] Item 17. The salt of Item 14, which is substantially isolated.

[0647] Item 18. The salt of Item 14, characterized by a DSC thermogram having an endothermic peak at about 289.4°C.

[0648] Item 19. A salt as described in Item 14, wherein the salt has substantially Fig.11 DSC thermogram shown.

[0649] Item 20. A salt as described in Item 14, wherein the salt has substantially Fig.12 TGA thermogram shown.

[0650] Item 21. The salt of Item 14, which has at least one XRPD peak in terms of 2θ selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9°.

[0651] Item 22. The salt of Item 14, which has at least two XRPD peaks in terms of 2θ selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9°.

[0652] Item 23. The salt of Item 14, which has at least three XRPD peaks in terms of 2θ selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9°.

[0653] Item 24. The salt of Item 14, which has at least four XRPD peaks in terms of 2θ selected from about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9°.

[0654] Item 25. The salt of Item 14, comprising the following XRPD peaks in terms of 2θ: about 5.3°, about 8.5°, about 15.3°, about 20.1°, and about 24.9°.

[0655] Item 26. A salt as described in Item 14, wherein the salt has substantially Fig.10 XRPD distribution shown.

[0656] Item 27. A salt selected from:

[0657] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide phosphate;

[0658] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate;

[0659] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide hydrochloride;

[0660] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide salicylate;

[0661] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide methanesulfonate; and

[0662] N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide ethanesulfonate.

[0663] Item 28. A pharmaceutical composition comprising the salt of any one of Items 1 to 27 and a pharmaceutically acceptable carrier.

[0664] Item 29. A method for inhibiting TAM kinase, the method comprising: contacting the TAM kinase with a salt as described in any one of Items 1 to 27.

[0665] Item 30. A method of inhibiting AXL and MER kinases, the method comprising: contacting the AXL and MER kinases with a salt as described in any one of Items 1 to 27.

[0666] Item 31. A method of treating cancer in a patient, the method comprising administering to the patient a therapeutically effective amount of a salt as described in any one of Items 1 to 27.

[0667] Item 32. A method as described in Item 31, wherein the cancer is selected from hepatocellular carcinoma, bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, ovarian cancer, prostate cancer, esophageal cancer, gallbladder cancer, pancreatic cancer, thyroid cancer, skin cancer, leukemia, multiple myeloma, chronic lymphocytic lymphoma, adult T-cell leukemia, B-cell lymphoma, acute myeloid leukemia, Hodgkin's lymphoma or non-Hodgkin's lymphoma, Waldenstrom's macroglobulinemia, hairy cell lymphoma, Burkitt's lymphoma, glioblastoma, melanoma and rhabdomyosarcoma.

[0668] Item 33. A method as described in Item 31, wherein the cancer is lung cancer, prostate cancer, colon cancer, breast cancer, melanoma, renal cell carcinoma, multiple myeloma, gastric cancer or rhabdomyosarcoma.

[0669] Item 34. A method for preparing a salt as described in Item 1, the method comprising making a compound of formula I:

[0670]

[0671] Reaction with maleic acid to form the salt.

[0672] Item 35. The method of Item 34, wherein about 1 equivalent of maleic acid is used based on 1 equivalent of the compound of Formula I.

[0673] Item 36. The method of Item 34, wherein the reacting the compound of Formula I with maleic acid is carried out in the presence of a solvent component.

[0674] Item 37. The method of Item 36, wherein the solvent component comprises methanol.

[0675] Item 38. The method of Item 36, wherein the solvent component comprises dichloromethane.

[0676] Item 39. The method of Item 36, wherein the solvent component comprises methanol and dichloromethane.

[0677] Item 40. A method as described in Item 39, wherein the method also includes removing a majority of the dichloromethane to allow the salt to precipitate.

[0678] Item 41. The method of Item 36, wherein the method further comprises forming a solution of the compound of Formula I in a solvent component prior to the reacting.

[0679] Item 42. The method of Item 41, wherein the solution is formed by heating a slurry of the compound of Formula I in the solvent component to a temperature of about 45°C to about 55°C.

[0680] Item 43. A method as described in Item 42, wherein the method further includes stirring the solution before reacting the compound of Formula I with maleic acid; and filtering the solution to form a filtrate.

[0681] Item 44. A method as described in Item 43, wherein the method further includes adding activated carbon and silica gel to the solution after the step of heating the slurry to a temperature of about 45°C to about 55°C to form a solution and before the step of stirring the solution.

[0682] Item 45. A method for preparing a salt as described in Item 14, the method comprising making a compound of formula II:

[0683]

[0684] Reaction with sulfuric acid to form the salt.

[0685] Item 46. The method of Item 45, wherein about 0.6 equivalents of sulfuric acid are used based on 1 equivalent of the compound of Formula II.

[0686] Item 47. The method of Item 45 or 46, wherein the method comprises:

[0687] adding the compound of formula II to the solvent component to form a solution;

[0688] adding sulfuric acid to the solution at room temperature;

[0689] concentrating the solution to form a slurry;

[0690] Stirring the slurry at a temperature of about 60°C to about 70°C; and

[0691] The slurry is cooled to a temperature of about 15°C to about 25°C to precipitate the salt.

[0692] Item 48. The method of Item 47, wherein the solvent component comprises methanol.

[0693] Item 49. The method of Item 47, wherein the solvent component comprises dichloromethane.

[0694] Item 50. The method of Item 47, wherein the solvent components comprise methanol and dichloromethane.

[0695] Item 51. A method as described in Item 47, wherein the sulfuric acid is an approximately 1M aqueous solution.

[0696] Item 52. A method as described in Item 45, wherein the method includes preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate.

[0697] Item 53. A method as described in Item 52, wherein the method for preparing a salt in the form of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate comprises reacting a compound of formula II with approximately 1 equivalent of sulfuric acid based on 1 equivalent of the compound of formula II.

[0698] Item 54. A method as described in Item 52 or 53, wherein the method for preparing N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazine-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate comprises:

[0699] Adding the compound of formula II to the first solvent component at room temperature to form a solution;

[0700] heating the solution to a temperature of about 50°C to about 60°C;

[0701] adding sulfuric acid to the solution; and

[0702] The solvent is removed to precipitate the sulfate salt.

[0703] Item 55. The method of Item 54, wherein the first solvent comprises methanol.

[0704] Item 56. A method as described in Item 54, wherein the sulfuric acid is added in the form of an aqueous solution.

[0705] Item 57. The method of Item 52 or 53, further comprising the following steps:

[0706] adding the N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-phenyl-1,2,3,4-tetrahydropyrimidine-5-carboxamide sulfate to the second solvent component to form a slurry;

[0707] heating the slurry to a temperature of about 30°C to about 40°C;

[0708] stirring the slurry; and

[0709] The resulting hemisulfate salt was collected.

[0710] Item 58. The method of Item 57, wherein the second solvent component comprises water.

[0711] Item 59. The method of Item 57, further comprising preparing an amorphous form of the hemisulfate salt, wherein the preparing the amorphous form of the hemisulfate salt comprises the following steps:

[0712] adding the hemisulfate salt to a third solvent component at room temperature to form a solution;

[0713] filtering the solution;

[0714] concentrating the filtrate; and

[0715] The resulting solid is dried to obtain the amorphous hemisulfate salt.

[0716] Item 60. The method of Item 59, wherein the third solvent component comprises acetone and methanol.

Claims

1. A salt, which is N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide maleate.

2. The salt of claim 1 which is a 1:1 stoichiometric ratio of N-(4-(4-amino-7-(1-isobutyrylpiperidin-4-yl)pyrrolo[1,2-f][1,2,4]triazin-5-yl)phenyl)-1-isopropyl-2,4-dioxo-3-(pyridin-2-yl)-1,2,3,4-tetrahydropyrimidine-5-carboxamide to maleic acid.

3. The salt according to claim 1, which is a crystalline salt.

4. The salt of claim 1 which is a substantially isolated salt.

5. The salt of claim 1 characterized by a DSC thermogram having an endothermic peak at about 211°C.

6. The salt of claim 1 having a DSC thermogram substantially as shown in FIG.

2.

7. The salt of claim 1 having a TGA thermogram substantially as shown in FIG3.

8. The salt of claim 1, having at least one XRPD peak in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

9. The salt of claim 1, having at least two XRPD peaks in terms of 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.

10. The salt of claim 1, having at least three XRPD peaks in 2θ selected from about 4.3°, about 8.4°, about 12.6°, about 13.2°, and about 18.5°.